Stem Cell Factor and Hematopoiesis

Blood online

SEARCH:

Advanced

This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Citation Map

Services

Email this article to a friend

Similar articles in this journal

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Rights and Permissions

Citing Articles

Citing Articles via HighWire

Citing Articles via CrossRef

Citing Articles via Google Scholar

Google Scholar

Articles by Broudy, V. C.

Search for Related Content

PubMed

PubMed Citation

Articles by Broudy, V. C.

Related Collections

Review Articles

Social Bookmarking


What's this?

Next Article

Blood, Vol. 90 No. 4 (August 15), 1997: pp. 1345-1364

REVIEW ARTICLE

Stem Cell Factor and Hematopoiesis

By Virginia C. Broudy
From the Department of Medicine, University of Washington, Seattle, WA.

  INTRODUCTION

Introduction
References

HEMATOPOIESIS is governed by a number of cytokines that promote the survival, proliferation, and differentiation of hematopoietic stem cells and progenitor cells.¹ Stem cell factor (SCF; also known as kit ligand, mast cell growth factor, or steel factor) is a hematopoietic cytokine that triggers its biologic effects by binding to its receptor, c-kit.^2-5 A host of naturally occurring mutations at the Sl locus or at the W locus, which encode SCF and the c-kit receptor, respectively, has been identified⁶^,⁷ and molecularly characterized (reviewed in Besmer et al⁸ ). These mutations provide insights into the role of SCF and the c-kit receptor in vivo. Absence of SCF protein (the Sl mutation) or absence of cell surface c-kit receptor display (the W mutation) result in death in utero or in the perinatal period with severe macrocytic anemia. Absence of c-kit receptor kinase activity (the W⁴² mutation)⁹ also causes perinatal death with severe macrocytic anemia. These observations indicate that SCF plays an essential role during development in utero.

Point mutations in the c-kit receptor that diminish its tyrosine kinase activity or mutations that alter SCF production are associated with a spectrum of phenotypic abnormalities, including variable degrees of macrocytic anemia, decreased numbers of tissue mast cells, decreased fertility, and decreased pigmentation.¹⁰ These observations demonstrate a role for SCF and its receptor c-kit in hematopoiesis and in development of germ cells and melanocytes. Development of the interstitial cells of Cajal, which are responsible for intestinal pacemaker activity, is defective in mice with mutations at the Sl or W loci.¹¹^,¹² In general, the severity of the defect in c-kit receptor kinase activity parallels the severity of the phenotypic abnormalities that result.¹³

SCF is normally found in both soluble and transmembrane forms¹⁴ (Fig 1, described in detail below). The Sl^d mutation (deletion of the transmembrane and cytoplasmic domains of SCF ) results in production of soluble SCF and absence of transmembrane SCF.¹⁴^,¹⁵ Sl/Sl^d mice are viable, but have severe macrocytic anemia, markedly reduced tissue mast cells, and are sterile and white.⁶ The phenotype of the Sl/Sl^d mouse indicates that the presence of soluble SCF is not sufficient to completely compensate for the lack of transmembrane SCF and suggests that the transmembrane form of SCF may play a unique role in vivo.

View larger version (22K):
[in this window]
[in a new window]
Fig 1. Soluble and transmembrane forms of human SCF. The primary proteolytic cleavage site of SCF²⁴⁸ in exon 6 is indicated by the arrow. Cleavage at this site generates the soluble form of SCF. The transmembrane form of SCF, SCF²²⁰, lacks the primary proteolytic cleavage site in exon 6. The 25 amino acid signal sequence (dotted lines) and the hydrophobic transmembrane domain (dark box) are also shown. As described in the text, murine SCF²⁴⁸ and murine SCF²²⁰ can also be cleaved at an alternative site in exon 7.

During embryonic life, SCF and c-kit receptor RNA are expressed along the migratory pathways and in destinations of primordial germ cells and melanocytes, in sites of hematopoiesis (including the yolk sac, fetal liver, and bone marrow), in the gut, and in the central nervous system.^16-18 This pattern of expression suggests that SCF may influence the migration of germ cells, melanocytes, and hematopoietic cells to their ultimate destinations during development. Hematopoietic cells expressing the c-kit receptor protein were detected at gestational day 8 in the embryonic yolk sac and by day 10 in fetal liver, where they progressively increased until day 15 and then decreased,¹⁹ paralleling the transition from yolk sac to fetal liver to bone marrow hematopoiesis. Fetal thymus also contains c-kit receptor-positive primitive T-lymphocyte and B-lymphocyte progenitors.¹⁹ Although the brain and spinal cord develop normally in mice with mutations at the Sl or W loci, these mice demonstrate subtle learning and memory defects.²⁰

In addition to its essential role during development, SCF is also important during adult life. Treatment of adult mice with a neutralizing anti-c-kit receptor monoclonal antibody (ACK2) causes pancytopenia and markedly decreases bone marrow cellularity,²¹ suggesting that constitutive production of SCF by marrow endothelial cells and fibroblasts²²^,²³ may be required for maintenance of normal basal hematopoiesis. SCF is also required for acute erythroid expansion during recovery from hemolytic anemia in adult mice.²⁴ Spermatogenesis,²⁵ melanocyte development,²⁶ gut motility,¹² and response to intestinal helminth infection²⁷ are impaired by ACK2 antibody treatment.

This review will briefly discuss the production and structure of SCF and will focus on the physiologic role of SCF in hematopoiesis. The cellular distribution of the c-kit receptor will also be described. Potential clinical uses for SCF and therapeutic approaches based on the c-kit receptor will be discussed.

  SCF PRODUCTION

SCF is encoded by the Sl locus on mouse chromosome 10^4,5,28 and has been mapped to human chromosome 12q22-12q24.²⁹^,³⁰ The structural organization of the SCF gene has been recently reviewed.³¹

The soluble and transmembrane forms of SCF are generated by alternative splicing that includes or excludes a proteolytic cleavage site (Fig 1).²⁹^,³² Both the soluble and the transmembrane form of SCF are biologically active.³³^,³⁴ SCF²⁴⁸ includes exon 6, which encodes a proteolytic cleavage site, resulting in the production of soluble SCF. The cleavage occurs after Ala¹⁶⁵. The lack of exon 6 in human SCF²²⁰ results in production of the transmembrane form of human SCF. In SCF²²⁰, amino acids 149-177 are replaced by a Gly residue. The ratio of SCF²⁴⁸ mRNA to SCF²²⁰ mRNA varies considerably in different tissues, ranging from 10:1 in the brain and 4:1 in the bone marrow to 0.4:1 in the testis.³²^,³⁵ Studies of normal human bone marrow fibroblasts confirm that these marrow stromal cells contain predominantly SCF²⁴⁸ mRNA.²³ The mechanisms that control the tissue-specific³² and developmentally regulated³⁶ production of SCF²⁴⁸ vs SCF²²⁰ are not well understood.

Soluble murine SCF can be generated by cleavage of murine SCF²⁴⁸ at the site in exon 6 or by cleavage of murine SCF²⁴⁸ or murine SCF²²⁰ at an alternative site in exon 7. A fibroblast cell line (Sl/Sl⁴ ), derived from the liver of a fetal Sl/Sl mouse that contains no SCF mRNA,³⁴ was engineered to express murine SCF²⁴⁸ or murine SCF²²⁰.³⁷ Both the Sl/Sl⁴ murine SCF²⁴⁸ and the Sl/Sl⁴ murine SCF²²⁰ cell lines were found to produce soluble SCF,³⁷ suggesting the existence of a secondary proteolytic cleavage site for murine SCF.³²^,³⁷ Deletion of 12 nucleotides (encoding Lys¹⁷⁸-Lys¹⁸¹ ) in exon 7 of murine SCF prevented release of soluble SCF, thus identifying a second proteolytic cleavage site that is unique to murine SCF.

The cleavage of SCF from the cell surface can be induced by activation of protein kinase C or by agents that increase cytosolic calcium levels.³² Two serine protease inhibitors prevented the cleavage of murine SCF²⁴⁸ but not that of murine SCF²²⁰, suggesting that cleavage at the sites in exon 6 and exon 7 may be differentially regulated.³⁸ However, certain protease inhibitors affect protein transport to the cell surface rather than protein cleavage at the cell surface, and a recent report suggests that a family of metalloproteases may release the soluble form of many cell surface proteins.³⁹

SCF is constitutively produced by endothelial cells and by fibroblasts.²²^,²³^,⁴⁰ These cells display the transmembrane form of SCF on the cell surface and also release soluble SCF. Keratinocytes in normal skin⁴¹ and epithelial cells in the gut⁴²^,⁴³ produce SCF, and SCF protein can be detected in the thymus⁴⁴ as well as in other sites.^45-47 Enriched populations of human hematopoietic stem cells and progenitor cells (CD34⁺ c-kit receptor⁺) are reported to contain SCF mRNA detectable by reverse transcription polymerase chain reaction.⁴⁸ Inflammatory stimuli such as interleukin-1 (IL-1) or tumor necrosis factor (TNF ) may modestly enhance SCF protein production by marrow stromal cells,²²^,²³ in contrast to their profound ability to increase granulocyte-macrophage colony-stimulating factor (GM-CSF ) and granulocyte colony-stimulating factor (G-CSF ) production.⁴⁹ Exposure of endothelial cells to transforming growth factor $beta$ ₁ (TGF $beta$ ₁ ) can decrease SCF mRNA content and SCF production in vitro.⁵⁰

The concentration of SCF in normal human serum is, on average, 3.3 ng/mL.⁵¹ Studies of patients with aplastic anemia, myelodysplasia, and a number of other types of chronic anemia have shown no increase in serum SCF levels.^52-54 Thus, the level of SCF in the circulation, unlike the level of erythropoietin (Epo), is not inversely related to the hematocrit. Serum SCF levels do not increase during the period of profound pancytopenia in patients undergoing marrow ablative chemoradiotherapy and stem cell transplantation.⁵⁵ Myelosuppressive chemotherapy or radiation therapy can increase SCF mRNA levels in murine bone marrow,⁵⁶^,⁵⁷ but whether this results in increased display of the transmembrane form of SCF within the marrow microenvironment is not known. Alterations in the local distribution of SCF within the skin have been described in patients with cutaneous mastocytosis⁴¹ and may play a role in the pathogenesis of this disorder.

  SCF STRUCTURE

The soluble form of SCF circulates as a noncovalently bonded dimer, is glycosylated, and has considerable secondary structure, including regions of $alpha$ helices and $beta$ sheets.⁵^,^58-60 The molecular weight of the soluble form of SCF calculated from its amino acid sequence is approximately 18,500 daltons. Expression of SCF in Chinese hamster ovary cells results in proteins of 28,000 to 40,000 daltons, indicating the presence of extensive and heterogenous glycosylation.⁵⁸^,⁶¹ Human SCF expressed in Chinese hamster ovary cells is approximately 30% carbohydrate by weight⁵⁸ and contains both N-linked and O-linked carbohydrate, both with attached sialic acid. The glycosylation sites of SCF have been characterized in detail.⁶²

The 4 Cys residues of SCF are involved in intramolecular disulfide bonds⁶² (Fig 2). The disulfide pairs are Cys⁴-Cys⁸⁹ and Cys⁴³-Cys¹³⁸. Truncation mutagenesis of the carboxy-terminal region of soluble SCF reveals that biologic activity is diminished when the region containing Cys¹³⁸ is deleted, suggesting that the Cys⁴³-Cys¹³⁸ bond may be important for full biologic activity⁶³; subsequent work suggests that both intramolecular disulfide bonds are critical to maintain SCF in a fully biologically active conformation.⁶⁴ Although an active dimeric form of SCF with 4 intermolecular disulfide bonds has been identified during oxidation and refolding of recombinant SCF expressed in Escherichia coli,⁶⁵ neither Chinese hamster ovary-expressed SCF nor native SCF dimers have been reported to contain intermolecular disulfide bonds, so it seems unlikely that this form of SCF plays a major role in vivo.

View larger version (42K):
[in this window]
[in a new window]
Fig 2. A molecular model of human SCF structure. The model is based extensively on the published structure of human M-CSF (Modified and reprinted with permission from Pandit et al.⁶⁹ Copyright 1992 American Association for the Advancement of Science.) and the M-CSF/SCF alignment of Bazan.⁶⁶ The SCF four helix bundle with two long overhand loops is shown as a ribbon diagram. The location of the two intramolecular disulfide bonds is shown in yellow, and the helix boundaries are indicated in the single amino acid code. The interhelical loop lengths have been altered from the M-CSF structure to account for the slightly longer predicted loops of SCF. Tyr²⁶ may be part of the dimer interface for SCF; this residue corresponds to Cys³¹ of M-CSF, the site of the single M-CSF interchain disulfide bond (Cys³¹-Cys³¹ ).

View larger version (188K):
[in this window]
[in a new window]
Fig 4. Autoradiographic analysis of ¹²⁵I-SCF binding to a normal human megakaryocyte. A multitude of grains is associated with the megakaryocyte, indicating that these cells display the c-kit receptor.

SCF shares a number of features with macrophage colony-stimulating factor (M-CSF ),⁶⁶ including dimeric structure, the existence of soluble and transmembrane forms generated by alternative splicing of a proteolytic cleavage site in exon 6, homologous intramolecular disulfide bonds, and homology between their receptors, c-kit and c-fms.⁶⁷^,⁶⁸ M-CSF contains 3 additional Cys residues (beyond the 4 Cys residues found in SCF ), one of which is involved in an intermolecular disulfide bond between the two M-CSF monomers.⁶⁹ It has been speculated that the relatively large area of contact at the surface of the two SCF monomers, even in the absence of an intermolecular disulfide bond, may suffice for stable dimer formation.⁶⁹ Whether the transmembrane form of SCF is a dimer like the soluble form of SCF, is not known.

Rat and human SCF have roughly equivalent bioactivity on human hematopoietic cells, but rat SCF is 800-fold more active on a murine cell line than is human SCF.⁷⁰ Rat SCF has a 100-fold higher binding affinity for the murine c-kit receptor than does human SCF.⁷¹ These observations have permitted the use of interspecies chimera to investigate the sequences of SCF required for bioactivity.⁷² Regions of the first, third, and fourth helices of SCF have been implicated as being essential for biologic activity.⁷² A splicing defect in the cytoplasmic tail of SCF in Sl/Sl^17H mice results in male sterility,⁷³ suggesting that an intact cytoplasmic domain of SCF may be important for normal function, although this mutation may also alter the stability of transmembrane SCF.

Amino-terminal and carboxy-terminal truncation of soluble human SCF has identified amino acids 1-141 as being essential for full biologic activity in vitro, assessed by ability to support proliferation of a factor-dependent cell line and ability to competitively displace binding of ¹²⁵I-SCF^1-165 to the c-kit receptor.⁷⁴ Absence of amino acids 1-3 partially impaired both cell proliferation and receptor binding activity, whereas deletion of amino acid 4 or beyond completely ablated both activities. It is of interest that SCF truncation mutant 1-127 retained full receptor binding activity but had reduced ability to support cell proliferation, suggesting that receptor binding and receptor activation can be dissociated.⁷⁴

  SCF AND HEMATOPOIESIS

Elizabeth Russell first suggested that the W and Sl loci might encode a receptor-ligand pair that was critical for hematopoiesis in vivo.⁶ The seminal observations that marrow from W mutant mice could not reconstitute hematopoiesis when transplanted into irradiated hosts,⁷⁵ that Sl marrow microenvironmental cells could not fully support hematopoiesis in vitro,⁷⁶ and that transplantation of normal splenic tissue into Sl/Sl^d mice improved hematopoiesis⁷⁷^,⁷⁸ indicated that the W defect was intrinsic to hematopoietic cells, whereas the Sl defect was intrinsic to marrow and splenic microenvironmental cells. The marrows of W/W^v and Sl/Sl^d mice contain fewer colony-forming units-spleen (CFU-S; W/W^v), burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte-macrophage (CFU-GM), and colony-forming unit-erythroid (CFU-E) than do littermate controls.^79-83 Subsequent studies in vitro have shown that SCF acts on hematopoietic stem cells and progenitor cells and, in some lineages, precursor cells and mature cells as well.

SCF can act directly on an enriched population containing hematopoietic stem cells to accelerate their entry into cell cycle.⁸⁴ SCF alone transiently maintained the long-term repopulating ability of Rhodamine^low, Lin^-, Sca-1⁺ populations of murine hematopoietic cells, suggesting that SCF can promote the survival of hematopoietic stem cells in vitro.⁸⁵ Self-renewal of stem cells in vitro in the presence of SCF alone or in the presence of SCF, IL-6, and Epo was not found.⁸⁵^,⁸⁶ Stem cells can survive on a stromal cell line even in the presence of the ACK2 anti-c-kit receptor antibody, suggesting that other cytokines produced by the stromal cells can support stem cell survival in the absence of SCF activity.⁸⁷ Brief exposure of murine marrow cells to a cytokine cocktail (SCF, IL-3, IL-6, and IL-11) expanded the number of progenitor cells but impaired long-term repopulating ability, sounding a cautionary note for ex vivo expansion protocols.⁸⁸ Inclusion of IL-3 in a combination of growth factors used for ex vivo expansion reduced the B- and T-lymphocyte potential and the long-term reconstituting ability of murine hematopoietic cells,^89-91 suggesting that IL-3 can promote differentiation at the expense of maintenance of true stem cell activity. However, murine marrow cells cultured in SCF plus IL-11 retained long-term repopulating activity and could be serially transplanted up to quartenary recipients.⁹² Sustained stem cell self-renewal in vivo may also be dependent on SCF.⁹³

Cells that give rise to spleen colonies in vivo (CFU-S) survive in vitro in the presence of SCF, and SCF in conjunction with IL-3 can increase the production of CFU-S over a 2-week period in vitro.⁹⁴ Blocking the c-kit receptor with the ACK2 antibody markedly reduced the survival of CFU-S in vitro,⁹⁵ although cells capable of initiating long-term bone marrow cultures (LTBMC-IC; defined by the ability to generate CFU-GM over a 5-week period in vitro) survived. Sl/Sl and normal fibroblasts supported LTBMC-IC equivalently, arguing that SCF is not required for LTBMC-IC survival.⁹⁶ Human LTBMC-IC underwent self renewal and 50-fold expansion in the presence of a cytokine cocktail that, for optimal LTBMC-IC expansion, included SCF.⁹⁷

SCF, in concert with IL-3 or other cytokines, increased the number of BFU-E, CFU-GM, and colony-forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) produced approximately 20-fold in liquid culture over a 1- to 4-week period in vitro,⁹⁸^,⁹⁹ indicating that SCF can act on a more primitive cell (pre-CFU-C) capable of generating the direct colony-forming cells. These observations^98-101 have formed the basis for ex vivo expansion protocols for human hematopoietic progenitor cells. Combinations of 5 cytokines (SCF, Epo, IL-1, IL-3, and IL-6) resulted in up to a 200-fold expansion of BFU-E, CFU-GM, and CFU-GEMM over a 2-week period in vitro from mobilized human peripheral blood CD34⁺ cells¹⁰²; LTBMC-IC cells did not expand under these conditions.¹⁰³ Ex vivo expanded populations of cells have been reinfused into patients following myelosuppressive chemotherapy.¹⁰⁴ Because these were autologous transplants in patients who did not receive myeloablative chemotherapy, the contribution of the infused stem cells to long-term hematopoiesis could not be stringently assessed,¹⁰⁴ and it is not clear that the infusion of these cells accelerated hematopoietic reconstitution. Other SCF-containing combinations of cytokines are also effective in amplifying the number of BFU-E, CFU-GM, and CFU-GEMM generated in liquid culture.^105-108

SCF synergizes with other cytokines (including Epo, IL-3, GM-CSF, and G-CSF ) to support the direct colony growth of BFU-E, CFU-GM, and CFU-GEMM in semisolid media.⁹⁸^,^109-114 Although SCF alone has modest effect on colony growth, in the presence of other cytokines SCF increases both the size and the number of colonies. The combinations of SCF plus IL-9 or SCF plus IL-7 have also been reported to synergistically promote BFU-E or CFU-GM colony growth, respectively.¹¹⁵^,¹¹⁶ SCF can also promote progenitor cell survival.¹¹⁷ SCF is required for BFU-E growth under serum-free conditions,¹¹⁸ and CD34⁺ hematopoietic cells cultured in the presence of SCF plus IL-3 can generate CFU-E,¹¹⁹ suggesting that the deficiency of CFU-E numbers in the marrow or fetal liver of Sl or W mutant mice¹²⁰ may be due to lack of SCF synergistic activity.¹¹⁹^,¹²¹^,¹²² Interaction between the c-kit and Epo receptors¹²³ may be essential to enable CFU-E to proliferate and differentiate in response to Epo.¹²⁴ The combination of SCF, IL-6, and soluble IL-6 receptor can support the proliferation, differentiation, and terminal maturation of BFU-E in vitro, even in the absence of Epo.¹²⁵ Reports that SCF can reactivate fetal hemoglobin synthesis in BFU-E colonies¹²⁶ and can retard differentiation of CFU-E in vitro¹²⁷ may reflect the potent synergistic effect of SCF on the proliferation of less mature erythroid progenitor cells. BFU-E, CFU-GM, and CFU-GEMM can migrate along an SCF gradient, suggesting that SCF can also function as a chemotactic and chemokinetic factor for progenitor cells.¹²⁸

Mice with mutations at the Sl and W loci have normal platelet counts,⁶ indicating that full SCF bioactivity is not an absolute requirement for platelet production in vivo. SCF alone is not a potent stimulant of colony-forming unit-megakaryocyte (CFU-Meg) proliferation or of megakaryocyte nuclear endoreduplication or cytoplasmic maturation in vitro.^129-132 However, SCF can synergistically enhance the ability of other cytokines such as Tpo, IL-3, and GM-CSF to promote CFU-Meg colony growth and to increase the size of CFU-Meg colonies.¹²⁹^,¹³⁰ The addition of SCF to IL-3 doubled the number of CFU-Meg generated in human long-term bone marrow cultures over a 3-month period, indicating the SCF can act on a more primitive population of cells capable of producing CFU-Meg.¹³⁰ SCF also promotes the growth but not the differentiation of human megakaryocytic cell lines in vitro.¹³¹ Thus, SCF predominantly exhibits synergistic proliferative effects on megakaryocytic progenitor cells, especially in combination with Tpo or IL-3.¹²⁹^,¹³⁰^,¹³² SCF can also potentiate the ability of epinephrine and ADP to induce the secondary wave of platelet aggregation and serotonin secretion.¹³³

  SCF AND MAST CELLS

The profound mast cell deficiency in W/W^v and Sl/Sl^d mice suggested that SCF may be required for mast cell production. Although the tissues of W/W^v or Sl/Sl^d mice contain less than 1% of the normal levels of mast cells,¹³⁴^,¹³⁵ mast cell progenitors are found in the marrow of these mice,¹³⁶^,¹³⁷ and treatment of Sl/Sl^d mice with SCF increases the number of mast cells in the skin.⁴ SCF promotes the survival, proliferation, and maturation of mast cells in vitro¹³⁸^,¹³⁹ (Table 1). The earliest committed mast cell progenitor, the pro-mastocyte, proliferates and differentiates in vitro in the presence of SCF plus IL-3.¹⁴⁰ Mast cells can be cultured from human bone marrow CD34⁺ cells,¹⁴¹ peripheral blood mononuclear cells,¹⁴² cord blood cells,¹⁴³ or fetal liver cells,¹⁴⁴ or from rodent marrow cells¹⁴⁵ in the presence of SCF. Optimal murine mast cell proliferation and differentiation in response to SCF may require cofactors such as IL-3, IL-4, or IL-10.¹⁴⁶ In cultures maintained in SCF for more than 3 months, mast cell production may predominate over granulocyte-macrophage production.¹⁴³

View this table:
[in this window] [in a new window]
Table 1. Effects of SCF on Mast Cells

SCF also promotes mast cell secretory function,¹⁴⁷^,¹⁴⁸ chemotaxis,¹⁴⁹ and adhesion¹⁵⁰ and can enhance secretion of mediators in response to IgE-dependent activation¹⁴⁸^,¹⁵¹ (Table 1). At concentrations similar to that found in normal human serum, SCF stimulates histamine and prostaglandin D₂ release from cultured human cutaneous mast cells.¹⁴⁸ However, brief preincubation of mast cells with substantially lower concentrations of SCF can potentiate IgE-dependent cutaneous mast cell mediator release.¹⁴⁷^,¹⁴⁸ At concentrations 10- to 100-fold lower than required to stimulate mast cell proliferation, SCF enhances histamine and leukotriene C₄ release from human lung mast cells in response to IgE receptor cross-linking.¹⁵¹ SCF can also potentiate IgE-dependent histamine released by human basophils, although basophils appear to be much less sensitive to SCF than are mast cells.¹⁴⁸ In murine mast cells, SCF can induce secretion of cytokines (including IL-6 and, to a lesser extent, TNF- $alpha$ ) at concentrations that induce little or no release of preformed mediators such as histamine.¹⁵² Mast cell chemotaxis in the direction of a gradient of SCF has also been reported.¹⁴⁹ The effects of SCF on mast cell adhesion to fibronectin or to fibroblasts are described in a subsequent section.

In preclinical studies, SCF treatment increased tissue mast cell numbers by greater than 100-fold¹⁵³^,¹⁵⁴ and induced mast cell activation in vivo.¹⁴⁷ The studies documenting the effects of SCF on mast cell proliferation, maturation, chemotaxis, and degranulation provide important information that may explain the principal toxicity that has been encountered with the use of SCF in vivo.¹⁵⁵

  SCF AND LYMPHOPOIESIS

B lymphopoiesis is relatively normal in mice with mutations at the Sl or the W loci.¹⁵⁶^,¹⁵⁷ B lymphopoiesis was not impaired in mice injected with the ACK2 anti-c-kit receptor antibody,¹⁵⁸ although erythroid and myeloid cells were virtually eliminated from the marrow.²¹ In fact, the number of pro-B cells, pre-B cells, and mature B cells increased twofold to fourfold in the mice treated with the ACK2 antibody.¹⁵⁸ Transplantation of W/W fetal liver cells into lymphocyte-deficient RAG-2^-/- mice resulted in development of all stages of B cells, demonstrating that signal transduction through the c-kit receptor is not essential for B lymphopoiesis in vivo.¹⁵⁹

The initial stages of B-cell development in vitro (production of pro-B cells and pre-B cells) requires factors produced by stromal cells, whereas the maturation of B lymphocytes does not depend on stromal cells.¹⁶⁰ Whether SCF is one of the stromal cell-derived factors that is essential for B lymphopoiesis has been intensely investigated. When individual primitive hematopoietic cells (Sca-1⁺ Lin^- cells that retain the potential to differentiate along the lymphoid or the myeloid lineages) were cultured in combinations of cytokines, SCF was effective in maintaining the B-lymphoid potential of these cells.¹⁶¹ However, the combination of flk-2/flt3 ligand plus IL-7 may be more potent that the combination of SCF and IL-7 in this respect.¹⁶² The most primitive cells that are committed to the B lineage (pro-B cells) do not proliferate in response to SCF, IL-7, or the combination of these two cytokines.¹⁶³ Pro-B-cell numbers increase as readily on Sl/Sl stromal cells (that do not produce SCF ) as on S17 stromal cells (that do produce SCF ), demonstrating that the growth of the pro-B cells depends on stromal cell factors distinct from SCF.¹⁶³ The differentiation of pro-B cells to pre-B cells also depends on stromal cell factors other than SCF.¹⁶⁴ SCF and IL-7 synergistically stimulate the proliferation of pre-B cells, but SCF is not required for the differentiation of pre-B cells to surface Ig⁺ B lymphocytes.¹⁶⁴^,¹⁶⁵ Likewise, the proliferative response of B lymphocytes to mitogens does not require SCF/c-kit receptor interaction.¹⁶⁵ These reports suggest that SCF exerts its predominant effect on B lymphopoiesis in vitro by enhancing the proliferative response of pre-B cells to IL-7.¹⁹

SCF plays a role in the early stages of T lymphocyte development in vivo.¹⁶⁶ The size of the most immature thymocyte compartment in neonatal W/W mice is 1/40 of that found in littermate control mice,¹⁶⁶ and W/W fetal liver cells do not contribute to thymopoiesis after transplantation into RAG-2^-/- mice.¹⁵⁹ Populations of normal CD4^- CD8^- CD3^- thymocytes can proliferate in vitro in response to the combination of SCF plus IL-7.⁴⁴^,¹⁶⁷ The ability of CD4^- CD8^- CD3^- thymocytes to reconstitute T-cell differentiation in explants of thymic tissue was ablated by the presence of the ACK2 anti-c-kit receptor antibody,¹⁶⁷ suggesting that SCF is critical for early T-lymphocyte development in this in vitro model. Likewise, Sl/Sl fetal thymic tissue, when implanted into a normal host, did not support production of CD4^-CD8^-CD3^- thymocytes as effectively as did normal fetal thymic tissue implants,¹⁶⁶ implying that SCF presentation by the thymic microenvironment is important. The development of intestinal intraepithelial lymphocyte populations is dysregulated in W/W^v and Sl/Sl^d mice,¹⁶⁸ suggesting that SCF/c-kit receptor interaction is important for normal function of the intestinal immune system. SCF may also affect mature T-cell function by potentiating the allogeneic mixed lymphocyte reaction.¹⁶⁹

Natural killer (NK) cells are a subset of large granular lymphocytes that are important for the immune response to viral infection and tumor cells. CD34⁺ human hematopoietic cells can differentiate into NK cells in vitro in the presence of SCF plus IL-2.¹⁷⁰ SCF also enhances the ability of CD56^bright NK cells to proliferate in response to IL-2.¹⁷¹ However, exposure to SCF did not increase the cytotoxicity of the CD56^bright NK cells against K562 cells (NK activity) or augment IL-2-induced LAK activity.¹⁷¹

Dendritic cells are efficient antigen-presenting cells that play a role in T-cell immunity. When CD34⁺ human marrow cells were cultured in GM-CSF plus TNF- $alpha$ , the addition of SCF increased the number of dendritic cell progenitors generated up to 100-fold, demonstrating that SCF can amplify dendritic cell progenitor numbers in vitro.¹⁷² SCF also synergized with GM-CSF and TNF- $alpha$ to directly increase the number of dendritic cells produced from CD34⁺ human marrow cells; the dendritic cells thus generated were capable of stimulating resting T cells in the allogeneic mixed leukocyte reaction.¹⁷²^,¹⁷³

  SCF AND ADHESION

Hematopoiesis occurs in close proximity to bone marrow stromal cells and to extracellular matrix molecules such as fibronectin.¹⁷⁴ A number of adhesive interactions maintain the intimate association of hematopoietic stem cells and progenitor cells and marrow stromal elements. Normal hematopoietic progenitor cells express the integrins VLA-4 and VLA-5¹⁷⁵ and can adhere in vitro to stromal cells that display VCAM-1¹⁷⁶ or to specific sites on fibronectin.¹⁷⁷^,¹⁷⁸ Adhesion to fibronectin declines with terminal erythroid differentiation¹⁷⁹ and may modulate progenitor cell proliferation.¹⁸⁰ Other adhesive interactions may also be important.¹⁷⁴^,¹⁸¹

Evidence that SCF can modulate the adhesive behavior of hematopoietic cells is derived from studies of mast cells,¹⁴^,¹⁵⁰^,^182-185 of hematopoietic cell lines,¹⁸⁶^,¹⁸⁷ and of normal hematopoietic cells.¹⁸⁷^,¹⁸⁸ Exposure to SCF increases adherence of CD34⁺ marrow cells to fibronectin,¹⁸⁷ and hematopoietic progenitor cells from W/W^v mice exhibit diminished basal adhesion to stromal cells.¹⁸⁹ Stimulation of mast cell adhesion to fibronectin requires 10- to 100-fold less SCF than does stimulation of mast cell proliferation in vitro.¹⁸²^,¹⁸⁵ SCF treatment initially increases (over 30 to 60 minutes) and then decreases (over 24 hours) adhesion of hematopoietic cell lines to VCAM-1 or to fibronectin.¹⁸⁶ These effects were mediated not by a change in the number of VLA-4 or VLA-5 molecules displayed on the hematopoietic cell surface, but by an alteration in their avidity for VCAM-1 or fibronectin. Other cytokines can also modulate VLA-4 and VLA-5 adhesive function.¹⁸⁷ Several of these reports document that SCF-induced cellular adhesion requires c-kit receptor kinase activity. These results suggest that the mechanism of SCF-induced progenitor cell adhesion to VCAM-1 or fibronectin may involve alteration of integrin avidity. An alternative possibility is that the transmembrane form of SCF displayed on fibroblasts binds directly to the c-kit receptor on the surface of hematopoietic cells and thus helps to anchor the hematopoietic cells in the microenvironment.¹⁴^,¹⁸³^,¹⁹⁰ The report that mast cells derived from W/W⁴² mice (that display the c-kit receptor protein on the cell surface but lack c-kit receptor kinase activity) can adhere normally to fibroblasts¹⁸⁴ provides support for the latter model. However, the preponderance of data argues that SCF binding to the c-kit receptor and activation of c-kit receptor kinase activity results in an inside-out signal that modulates integrin avidity on the surface of hematopoietic cells, thereby altering integrin adhesive function.^186-188

Because of the strong correlation between the ability of cytokines to induce hematopoietic progenitor cells to proliferate and to adhere to fibronectin, it has been proposed that the cytokine-induced inside-out signal that alters integrin avidity on the hematopoietic cell surface may be followed by an outside-in signal transmitted via the integrins that may promote cell proliferation in cooperation with the hematopoietic growth factors.¹⁸⁸ Likewise, SCF-induced enhancement of integrin avidity for fibronectin may potentiate phosphorylation of the focal adhesion kinase pp125^FAK,¹⁹¹ which plays a key role in integrin-mediated signalling.

Normal human endothelial cells display high-affinity c-kit receptors,⁴⁰ and it is possible that SCF binding to endothelial cells or to other marrow stromal cells could alter the adhesive phenotype of these cells. Stimulation of endothelial cells with SCF in vitro did not induce display of the adhesion molecules VCAM-1, ELAM-1, or ICAM-1.⁴⁰ A preliminary report indicates that SCF treatment of a marrow stromal cell line induced the expression of hemonectin, which could potentially mediate adhesion of progenitor cells.¹⁹²^,¹⁹³ Expression of human c-kit cDNA in porcine aortic endothelial cells conferred the ability to proliferate, to undergo cytoskeletal reorganization, and to migrate in response to human SCF,¹⁹⁴ demonstrating that these cells have the capacity to respond to SCF. The potential effects of SCF on the adhesive function of marrow stromal cells has not been fully explored.

  SCF AND HEMATOPOIETIC STEM CELL/PROGENITOR CELL MOBILIZATION

The mechanisms that govern the trafficking of hematopoietic stem cells and progenitor cells between the bone marrow and blood in vivo are not understood in detail. Injection of mice with SCF results in a profound redistribution of primitive hematopoietic cells from the bone marrow into the blood and spleen.¹⁹⁵^,¹⁹⁶ Primates treated with SCF demonstrate a 10- to 100-fold increase in the number of circulating progenitor cells and mobilization of cells that engraft lethally irradiated recipients.¹⁹⁷^,¹⁹⁸ Treatment of primates or mice with antibodies against the integrin VLA-4 or against its counter receptor VCAM-1 also results in egress of progenitor cells from the marrow into the blood,¹⁹⁹^,²⁰⁰ suggesting that interaction of VLA-4 expressed on hematopoietic cells and VCAM-1 constitutively displayed by microenvironmental cells may play a role in the trafficking of primitive hematopoietic cells in vivo. It is possible that SCF-induced mobilization of stem cells and progenitor cells from the bone marrow into the blood may be mediated in part by alterations in the interactions of hematopoietic cell integrins with VCAM-1 or fibronectin, but multiple mechanisms are likely to be involved.²⁰¹

Phase I clinical studies showed that treatment with SCF increases the numbers of progenitor cells of many types (including BFU-E, CFU-GM, CFU-Meg, and CFU-GEMM) in the marrow.²⁰² A randomized clinical trial in patients with ovarian cancer compared the ability of SCF plus G-CSF with that of G-CSF alone to mobilize LTBMC-IC²⁰³; all patients also received cyclophosphamide. Treatment with SCF resulted in a fivefold to sixfold increase in the number of LTBMC-IC mobilized, as well as an increase in the total number of CD34⁺ cells mobilized.²⁰³

Preclinical studies in mice showed that SCF treatment can expand the total number of stem cells capable of lymphohematopoietic reconstitution, as well as the numbers of CFU-S and direct colony-forming cells.^204-207 Hematopoietic cells obtained from mice previously treated with SCF or with SCF plus G-CSF were shown to be excellent targets for retrovirally mediated gene transfer^206,208; these studies have recently been extended to primates.²⁰⁹ The combination of SCF plus G-CSF synergistically increased the number of CFU-S in the blood and increased the short-term and long-term repopulating ability of the circulating murine hematopoietic cells.¹⁹⁶^,²⁰⁵^,²¹⁰ The murine hematopoietic cells mobilized by SCF plus G-CSF maintained marrow repopulating ability on serial transplantation, whereas the hematopoietic cells mobilized by G-CSF had poor repopulating function on secondary transplantation.²¹⁰ Thus, the population of cell mobilized by SCF plus G-CSF is functionally different than that mobilized by G-CSF alone. Autologous peripheral blood stem cell transplant studies in baboons showed that the use of cells mobilized with SCF plus G-CSF significantly accelerated neutrophil and platelet recovery in comparison to the use of cells mobilized with G-CSF alone.²¹¹ Whether the results of these preclinical studies will translate into clinical benefit in human peripheral blood stem cell transplantation remains to be seen.

  SCF AND RADIATION

Treatment with SCF alters sensitivity to radiation therapy. The increased radiosensitivity of mice with Sl and W mutations has long been known²¹² and may be due to the ability of SCF to suppress apoptosis and promote cell cycle progression.²¹³ Mice receiving SCF at specific times before radiation therapy were protected from radiation-induced death, possibly because SCF promotes hematopoietic cell entry into the relatively radioresistant S phase of the cell cycle.²¹⁴ Pretreatment with SCF also increases the survival of murine duodenal crypt stem cells, which may decrease radiation-induced gut toxicity.²¹⁵ Mice receiving SCF after radiation therapy demonstrated accelerated recovery of white blood cell and platelet counts.²¹⁶ Treatment of dogs with SCF after radiation therapy permitted survival despite otherwise lethal doses of radiation.²¹⁷ Conversely, neutralization of SCF activity increased sensitivity to radiation-induced death.²¹⁸ SCF as a single agent has generally not accelerated hematopoietic recovery when administered after myelosuppressive chemotherapy or stem cell/progenitor cell transplantation,^219-221 although the combination of SCF plus IL-11 may enhance neutrophil and platelet recovery.²²⁰

  DIFFERENTIAL EFFECTS OF SOLUBLE AND TRANSMEMBRANE SCF

The soluble and transmembrane forms of SCF display somewhat different effects in vitro. Transmembrane SCF expressed by a fibroblast cell line was able to support hematopoiesis (production of CFU-GM) for a several week longer period of time than was soluble SCF produced by the fibroblast cell line.³⁴ Transmembrane SCF is a more potent stimulant of primordial germ cell survival in vitro than is soluble SCF^222,223 and may also mediate binding of germ cells to Sertoli cells in the testis.³⁶ Soluble SCF appears to activate the c-kit receptor more transiently and to induce more rapid downregulation of cell surface c-kit receptor display than does transmembrane SCF.²²⁴ The duration of activation of the MAP kinase pathway can influence the cellular response (proliferation v differentiation) to the signal in a neuronal cell line²²⁵; it is possible that this concept could apply to signaling via the c-kit receptor as well. However, the basis for the differing effects of soluble and transmembrane SCF is not fully understood at present.

View larger version (60K):
[in this window]
[in a new window]
Fig 3. The c-kit receptor. The ATP binding site is found in the kinase domain proximal to the cell membrane. The phosphotransferase region is in the kinase domain distal to the cell membrane. As described in the text, a soluble form of the c-kit receptor generated by cleavage at a site near the membrane-spanning region has also been identified.

The phenotypes of Sl/Sl^d mice⁶^,¹⁴^,¹⁵ and of male Sl/Sl^17H mice⁷³ suggest that the presence of soluble SCF cannot fully overcome the lack of normally expressed transmembrane SCF. The Sl^d mutation may also diminish the quantity of soluble SCF produced; SCF activity was not detected in the supernatant of fibroblasts from Sl/Sl^d mice,¹³⁷ and administration of exogenous SCF to Sl/Sl^d mice increased mast cell numbers and hematocrit.⁴ Despite the low binding affinity of soluble human SCF for the murine c-kit receptor,⁷¹ transgenic expression of the transmembrane form of human SCF in mice resulted in abnormalities of coat color reminiscent of certain W alleles,²²⁶ suggesting that the human transmembrane SCF blocked the ability of native murine SCF to activate the c-kit receptor in melanocytes.

Transgenic expression of an obligate transmembrane form of murine SCF in Sl/Sl^d mice dramatically expanded erythropoiesis, but had little effect on myelopoiesis. In contrast, enforced expression of soluble murine SCF in the Sl/Sl^d mice increased myelopoiesis but not erythropoiesis.²²⁷ These results suggest that the presentation of SCF, whether in a transmembrane form by marrow microenvironmental cells or in a soluble form, may differentially influence the proliferation of erythroid and myeloid progenitor cells. As previously discussed, the transmembrane form of SCF may guide the migration of hematopoietic cells, germ cells, and melanocytes to their final destinations during embryogenesis¹⁷^,¹⁸ or may be required for melanocyte survival in the skin.²²⁸

  THE c-kit RECEPTOR

The c-kit receptor²²⁹ is a member of the type III receptor tyrosine kinase family⁶⁷^,⁶⁸ (reviewed in Ullrich and Schlessinger²³⁰ ). This family of cytokine receptors also encompasses the c-fms receptor, the platelet-derived growth factor (PDGF ) receptors, and flk-2/flt3 receptor. The structure of these receptors includes an extracellular domain with five Ig-like motifs, a single short membrane-spanning domain, and a cytoplasmic domain with tyrosine kinase activity (Fig 3). The kinase domain is interrupted by a kinase insert sequence that divides the kinase domain into an ATP binding region and phosphotransferase region. The c-kit receptor is a 145,000-dalton glycoprotein⁶⁷ and has been given the designation CD117. Binding of SCF (which circulates as a noncovalently associated dimer)⁵⁸ triggers c-kit receptor homodimerization and intermolecular tyrosine phosphorylation of the receptor, creating docking sites for a number of SH2-containing signal transduction molecules.²³¹ The signal transduction pathways employed by the c-kit receptor will not be covered in this review. An elegant genetic analysis suggests that a protein tyrosine phosphatase, SHP1, may terminate c-kit receptor signal transduction by modulating phosphorylation of downstream substrates of the c-kit receptor.²³²^,²³³

Deletion analysis and construction of chimeric human-mouse c-kit receptors have suggested that the three amino-terminal Ig-like domains of the c-kit receptor contain the SCF binding site and that the fourth Ig-like domain may contain a site required for c-kit receptor dimerization.^234-236 A recombinant soluble form of the c-kit receptor, truncated at the juncture of the extracellular and transmembrane domains, can bind SCF and undergo ligand-induced dimerization,^237-239 demonstrating that all of the structural information required for these processes is present in the extracellular domain of the receptor.

Alternative splicing results in two naturally occurring isoforms of the c-kit receptor that contain (designated kit A) or lack (designated kit) four amino acids (Gly Asn Asn Lys) at codon 510 just outside the transmembrane domain.²⁴⁰ These two c-kit receptor isoforms coexist in normal tissues. The ratio of kit A to kit mRNA in normal human bone marrow is approximately 1:5.²⁴¹ In marrow from patients with acute myelogenous leukemia, the ratio varies considerably, but there is no association with French-American-British subtype or clinical outcome.²⁴¹ The biologic significance of these two isoforms of the c-kit receptor remains unclear.

Point mutations in the c-kit receptor cytoplasmic domain have been identified in murine and human mast cell lines and in hematopoietic cells from patients with mast cell disorders. Mutation of Asp⁸¹⁴ in the kinase domain in a murine mast cell line and mutation of the corresponding amino acid (Asp⁸¹⁶ ) in a human mast cell line confer factor-independent growth, constitutive tyrosine phosphorylation of the c-kit receptor, mast cell differentiation, and tumorigenicity in vivo.^242-246 The Asp⁸¹⁶ mutation has also been found in peripheral blood mononuclear cells from patients with mastocytosis and an associated myelodysplastic disorder²⁴⁷ and in mast cells from patients with urticaria pigmentosa.²⁴⁸ Mutation of Asp⁸¹⁴ alters the substrate specificity of the c-kit receptor and results in ubiquitinization and accelerated degradation of SHP1,²⁴⁹ the tyrosine phosphatase that normally attenuates c-kit receptor signal transduction. A mutation of Val⁵⁵⁹ in the juxtamembrane region of the c-kit receptor, which has been identified in a human mast cell line, results in ligand-independent dimerization and constitutive activation of the c-kit receptor.²⁵⁰ Deletion of seven amino acids (Thr⁵⁷³-His⁵⁷⁹ ) in the juxtamembrane domain likewise resulted in constitutive activation of the c-kit receptor in a murine mast cell line.²⁵¹ Thus, structural and functional characterization of the c-kit receptor in mast cell lines or in cells from mastocytosis patients has identified single amino acid mutations and a short deletion in the cytoplasmic domain of the c-kit receptor that can be associated with neoplastic transformation of mast cells.

Mutations in the c-kit receptor have also been found in patients with the autosomal dominant disorder piebaldism.^252-255 Human piebaldism is characterized by a white hair forelock and hypopigmented patches on the trunk and extremities, reminiscent of the murine W (dominant white spotting) mutation. The hypopigmented areas of skin in individuals with piebaldism are devoid of melanocytes, possible due to failure of melanocyte migration during embryogenesis. Unlike the murine W mutation, anemia and infertility are not features of human piebaldism.

  CELLULAR DISTRIBUTION OF THE c-kit RECEPTOR

The c-kit receptor is broadly distributed within the hierarchy of hematopoietic cells and is also found in other tissues.²⁵^,⁴⁰^,⁴⁷^,¹²⁰ Cell populations enriched for murine hematopoietic stem cells, defined by the ability to reconstitute donor-derived lymphohematopoiesis in lethally irradiated hosts for more than 6 months, display the c-kit receptor on the cell surface.²⁵⁶ A study in which primitive murine hematopoietic cells were separated into c-kit receptor^<low and c-kit receptor^low populations and then transplanted into lethally irradiated recipients showed that both populations of cells could reconstitute lymphohematopoiesis in the primary recipients for at least 6 months.²⁵⁷ A report using a different transplant model (human hematopoietic cells transplanted into fetal sheep) showed that the CD34⁺ c-kit^low population of cells contained the long-term reconstituting activity.²⁵⁸ However, most reports,²⁵⁶^,^258-260 although not all reports,²⁶¹ agree that c-kit receptor^- purified populations of hematopoietic cells lack long-term reconstituting activity. Injection of a single murine hematopoietic cell with the phenotype CD34^low/-, c-kit receptor⁺, Sca-1⁺, Lin^- was capable of reconstituting lymphohematopoiesis for more than 6 months in a portion of recipient mice,²⁶² and donor-derived cells from recipient mice could repopulate lethally irradiated secondary recipients, convincingly demonstrating that the true lymphohematopoietic stem cell with extensive self-renewal capacity displays the c-kit receptor.²⁶²^,²⁶³

The cells that confer radioprotection when transplanted into irradiated recipients, also known as short-term repopulating cells, are also c-kit receptor⁺,²⁶⁰ as are CFU-S. In populations of human CD34⁺ hematopoietic cells, approximately 60% to 75% of the cells coexpress the c-kit receptor.²⁶⁴^,²⁶⁵ Thus, there is substantial but not complete overlap between the cellular distribution of the CD34 antigen and the c-kit receptor on hematopoietic cells.

Hematopoietic progenitor cells exhibit the c-kit receptor. When c-kit receptor⁺ hematopoietic cells are selected using a monoclonal antibody and cultured in direct colony-forming assays, the c-kit receptor⁺ population of cells is greatly enriched in BFU-E, CFU-GM, CFU-Meg, CFU-GEMM, LTBMC-IC, and CFU-E, whereas the c-kit receptor^- population of cells is depleted of colony-forming cells.²¹^,²⁵⁶^,^264-267 Cell sorting experiments based on detection of biotinylated SCF binding to marrow cells suggested that the density of c-kit receptor display on BFU-E is higher than on CFU-GM or on CFU-E.²⁶⁸ However, experiments using an anti-c-kit receptor monoclonal antibody showed similar density of c-kit receptor display on BFU-E, CFU-GM, and CFU-GEMM.²⁶⁹ The latter result suggests that the profound effect of SCF on erythropoiesis in vivo and in vitro, in comparison to its effects on myelopoiesis, is not due to differential receptor density at the progenitor cell level. The c-kit receptor can physically associate with the cytoplasmic domain of the Epo receptor in cells responsive to both cytokines; this observation may provide a molecular explanation for the potent synergistic effects of SCF and Epo on erythropoiesis.¹²³

Recognizable hematopoietic precursor cells also exhibit c-kit receptor on the cell surface. Autoradiographic analysis of ¹²⁵I-SCF binding to human or murine marrow cells demonstrates a plenitude of grains associated with recognizable erythroblasts, myeloblasts, and megakaryocytes (Fig 4) and a decrease in grain density in parallel to maturation.¹¹⁴^,²⁶⁵ Mast cells also exhibit c-kit receptors.²⁷⁰ Platelets display the c-kit receptor after activation with ADP; resting platelets are devoid of cell surface c-kit receptors.¹³³

The c-kit receptor is found on normal B- and T-lymphocyte progenitor cells as well.¹⁹ Approximately 85% of pro-B cells display the c-kit receptor.¹⁶³ A portion of pre-B cells also exhibit the c-kit receptor at low density; c-kit expression is lost as these cells mature to surface Ig⁺ B lymphocytes.¹⁵⁸^,¹⁶⁵ Of CD4^- CD8^- CD3^- thymocytes, approximately 30% exhibit the c-kit receptor.⁴⁴ As is true for B-lymphocyte progenitor cells, c-kit receptor density is highest on the least mature subpopulation of the CD4^- CD8^- CD3^- thymocytes.¹⁶⁷ These reports provide insights into c-kit receptor display during differentiation and maturation of normal hematopoietic cells and suggest a model in which the c-kit receptor is found at low density on primitive hematopoietic cells capable of long-term lymphohematopoietic reconstitution, increases in density to reach a peak at the progenitor cell level, and then decreases with terminal maturation of hematopoietic precursor cells.²⁷¹

Neoplastic human hematopoietic cells can also display the c-kit receptor. Virtually all patients presenting with acute myelogenous leukemia have c-kit receptor⁺ blasts, and SCF can stimulate the proliferation of these cells.^272-274 In contrast, leukemic blasts from patients with acute lymphocytic leukemia rarely display the c-kit receptor.²⁷²^,²⁷⁵ Most non-Hodgkin's lymphomas lack c-kit receptor expression,⁴⁰^,²⁷⁶^,²⁷⁷ with the exception of anaplastic large-cell lymphomas that can display the c-kit receptor.²⁷⁶ Lymph nodes from patients with Hodgkin's disease also express the c-kit receptor.²⁷⁶ The c-kit receptor is ubiquitously found on human hematopoietic cell lines of the erythroid and megakaryocytic phenotypes and on some myeloid and lymphoid cell lines as well.¹³¹^,²⁶⁵^,²⁷⁸ Receptor density is highest in erythroleukemia cell lines, which may express up to 50,000 to 100,000 c-kit receptors per cell.²³⁸ The majority of cell lines studied display a single class of high-affinity (kd of 50 to 200 pmol/L) binding sites; this is similar to the binding affinity found on normal human hematopoietic cells.²⁷⁹ A number of human solid tumor cell lines (including small cell lung cancer, breast cancer, and neuroblastoma) as well as a variety of fresh human tumor tissues (particularly small cell lung cancer, testicular seminoma, glioblastoma, and some breast cancer samples) have been shown to display the c-kit receptor protein.^280-284

  MODULATION OF c-kit RECEPTOR EXPRESSION

Display of the c-kit receptor on hematopoietic cells is modulated in a number of ways. Binding of SCF induces rapid internalization of the SCF-c-kit-receptor complex (see cover figure),²⁷⁰^,²⁸⁵^,²⁸⁶ likely via clathrin-coated pits.²⁸⁷ In parallel, the c-kit receptor is ubiquitinated and targeted for degradation by the proteasome proteolytic pathway.²⁸⁵^,²⁸⁶ Internalization and ubiquitination of the c-kit receptor requires the tyrosine kinase activity of the c-kit receptor, but not association and activation of PI 3' kinase.²⁸⁶ Treatment of cells with chloroquine partially blocks c-kit receptor degradation, suggesting that lysosomal proteases may also be involved.²⁸⁵ Whether a portion of the internalized c-kit receptors is parsimoniously recycled to the cell surface for reuse is unclear at present. Exposure of hematopoietic cells to TGF- $beta$ , TNF- $alpha$ , or IL-4 can downregulate cell surface c-kit receptor display by transcriptional or posttranscriptional mechanisms.^288-291 As described below, the c-kit receptor can also be proteolytically cleaved in the juxtamembrane region and shed from the cell surface^{40,238,270,292}; this process can be accelerated by activators of protein kinase C.

  SOLUBLE c-kit RECEPTOR

A number of cell surface cytokine receptors have soluble counterparts that are generated by alternative mRNA splicing or by proteolytic cleavage of the cell surface form of the receptor.²⁹³^,²⁹⁴ Many soluble receptors function as natural antagonists by competing with the cell surface receptor for cytokine binding. Soluble receptors may also function as carriers for the ligand to prolong ligand half-life in vivo,²⁹⁵ may mediate cytokine binding to transmembrane signal transduction subunits of the receptor,²⁹⁶ or may potentiate signal transduction via transmembrane receptor subunits even in the absence of the ligand by as yet unidentified mechanisms.²⁹⁷ Decreased cytokine receptor density on the cell surface is one mechanism that can attenuate cellular response to the cytokine.²⁹⁸ Whether soluble cytokine receptors normally serve to modulate ligand bioactivity in vivo or whether they are a byproduct of cellular desensitization to the ligand remains unclear at present.

Soluble c-kit receptor is released by human hematopoietic cells, mast cells, and endothelial cells⁴⁰^,²³⁸^,²⁷⁰^,²⁹² and circulates in normal human plasma at a concentration of approximately 325 ng/mL.²⁹⁹ The quantity of soluble c-kit receptor in the plasma exceeds that of SCF by a 30-fold molar ratio. Native soluble human c-kit receptor binds SCF with an affinity comparable to that of the cell surface form of the receptor.²³⁸ Recombinant soluble c-kit receptor can bind SCF and can antagonize SCF-induced tyrosine phosphorylation of the cell surface c-kit receptor in vitro.²³⁷ A form of recombinant soluble murine c-kit receptor, fused to the F_c domain of human IgG and thus an obligate dimer, binds murine SCF with high affinity (kd of 300 pmol/L) and blocks SCF-induced cell proliferation in vitro.³⁰⁰ The stoichiometry of interaction of SCF and recombinant soluble c-kit receptor is 2:2.²³⁹ These reports suggest that the quantity and binding affinity of the soluble c-kit receptor present in vivo are sufficient to modulate SCF bioactivity, although this has not been directly demonstrated.

  POTENTIAL CLINICAL USES FOR SCF

The potential cornucopia of clinical uses for SCF has been limited by the adverse events encountered in initial clinical trials.¹⁵⁵^,²⁰³ Dermal mast cell degranulation resulting in a pruritic wheal with surrounding edema at the SCF injection site occurs in most patients and resolves within 24 hours.¹⁵⁵^,²⁰³ Melanocyte proliferation and increased melanization of the epidermis, resulting in 3- to 5-cm diameter areas of increased skin pigmentation at SCF injection sites, has been reported in some patients receiving SCF at 5 to 50 µg/kg/d for 14 days.¹⁵⁵^,³⁰¹ The hyperpigmentation generally resolves after 2 to 12 months. Approximately 10% to 20% of the patients in two studies developed an allergic-like reaction characterized by urticaria, with or without respiratory symptoms suggestive of laryngeal edema, that required discontinuation of SCF treatment.¹⁵⁵^,²⁰³ The effects of SCF on mast cells appear to be dose-dependent,¹⁵⁵ and it is possible that the potent synergistic effects of SCF noted in vitro could be exploited in vivo. For example, low doses of SCF could be used in conjunction with G-CSF or other cytokines as a stem cell and progenitor cell mobilizing agent; clinical trials of SCF plus G-CSF are currently underway.²⁰³^,³⁰²^,³⁰³ The latter studies have shown an improved safety profile for SCF when used at lower doses. The incidence of allergic-like reactions was approximately 2% in 400 SCF-treated patients.³⁰³ Analogs of SCF with enhanced ability to stimulate the proliferation and modulate the adhesive function of hematopoietic cells yet no increased effect on mast cell activation have been designed³⁰⁴^,³⁰⁵ and are currently in preclinical trials (K. Nocka, personal communication, November 1996). Hematopoietic cells exposed to SCF either in vivo²⁰⁶^,²⁰⁸^,²⁰⁹ or in vitro³⁰⁶ are more efficiently transduced by retroviral vectors; this may prove useful for gene therapy. Ex vivo expansion of hematopoietic stem cells and progenitor cells is another potential use for SCF; many of the cytokine cocktails used for this purpose contain SCF.¹⁰⁴ Although the number of progenitor cells can be expanded many fold, whether the number of stem cells can actually be increased ex vivo with presently available techniques remains an area of debate.³⁰⁷^,³⁰⁸

Therapeutic approaches based on the c-kit receptor protein may eventually have clinical utility. Because the c-kit receptor is displayed on the surface of hematopoietic stem cells and progenitor cells, selection of these cells by immunoaffinity techniques (similar to those currently in clinical use to select hematopoietic cells expressing the CD34 antigen) may provide a population of cells useful for gene targeting and for transplantation.³⁰⁹ The recent success of retrovirally mediated gene transfer by targeting the erythropoietin receptor³¹⁰ and the use of an adenoviral vector linked to SCF to target cells expressing the c-kit receptor³¹¹ underscore the potential of this approach.

  NOTE ADDED IN PROOF

Recent results suggest that SCF may be predominantly monomeric at the concentration found in human serum³¹² and that the fourth Ig-like domain of the receptor is not required for SCF-induced c-kit receptor dimerization.³¹³

  FOOTNOTES

   Submitted December 3, 1996; accepted March 24, 1997.
   Supported by National Institutes of Health Grant No. DK44194 and by an American Cancer Society Faculty Research Award.
   Address reprint requests to Virginia C. Broudy, MD, Division of Hematology, University of Washington, Box 357710, Seattle, WA 98195-7710.

  ACKNOWLEDGMENT

The author thanks Drs Andrew Bohm and Kenneth Kaushansky for their assistance with Fig 2 and Drs Robert Andrews, George Demetri, Stephen Galli, Keith Langley, Karl Nocka, Thalia Papayannopoulou, and David Williams for helpful discussions and/or providing access to unpublished information.

  REFERENCES

Introduction
References

1. Metcalf D: Hematopoietic regulators: Redundancy or subtlety? Blood 82:3515, 1993[Free Full Text]
2. Williams DE, Eisenman J, Baird A, Rauch C, Ness KV, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, Burgess GS, Cosman D, Lyman SD: Identification of a ligand for the c-kit proto-oncogene. Cell 63:167, 1990[Medline] [Order article via Infotrieve]
3. Flanagan JG, Leder P: The kit ligand: A cell surface molecule altered in steel mutant fibroblasts. Cell 63:185, 1990[Medline] [Order article via Infotrieve]
4. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu R-Y, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213, 1990[Medline] [Order article via Infotrieve]
5. Huang E, Nocka K, Beier DR, Chu T-Y, Buck J, Lahm H-W, Wellner D, Leder P, Besmer P: The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225, 1990[Medline] [Order article via Infotrieve]
6. Russell ES: Hereditary anemias of the mouse: A review for geneticists. Adv Genet 20:357, 1979[Medline] [Order article via Infotrieve]
7. Geissler EN, McFarland EC, Russell ES: Analysis of pleiotropism at the dominant white-spotting (W) locus of the house mouse: A description of ten new W alleles. Genetics 97:337, 1981[Abstract/Free Full Text]
8. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF: The kit-ligand (steel factor) and its receptor c-kit/W: Pleiotropic roles in gametogenesis and melanogenesis. Development 125, 1993 (suppl)
9. Tan JC, Nocka K, Ray P, Traktman P, Besmer P: The dominant W⁴² spotting phenotype results from a missense mutation in the c-kit receptor kinase. Science 247:209, 1990[Abstract/Free Full Text]
10. Blouin R, Bernstein A: The white spotting and steel hereditary anemias of the mouse, in Feig SA, Freedman MH (eds): Clinical Disorders and Experimental Models of Erythropoietic Failure. Boca Raton, FL, CRC, 1993, p 157
11. Huizinga JD, Thuneberg L, Klüppel M, Malysz J, Mikkelsen HB, Bernstein A: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347, 1995[Medline] [Order article via Infotrieve]
12. Maeda H, Yamagata A, Nishikawa S, Yoshinaga K, Kobayashi S, Nishi K, Nishikawa S-I: Requirement of c-kit for development of intestinal pacemaker system. Development 116:369, 1992[Medline] [Order article via Infotrieve]
13. Reith AD, Rottapel R, Giddens E, Brady C, Forrester L, Bernstein A: W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 4:390, 1990[Abstract/Free Full Text]
14. Flanagan JG, Chan DC, Leder P: Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sl^d mutant. Cell 64:1025, 1991[Medline] [Order article via Infotrieve]
15. Brannan CI, Lyman SD, Williams DE, Eisenman J, Anderson DM, Cosman D, Bedell MA, Jenkins NA, Copeland NG: Steel-dickie mutation encodes a c-Kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 88:4671, 1991[Abstract/Free Full Text]
16. Orr-Urtreger A, Avivi A, Zimmer Y, Givol D, Yarden Y, Lonai P: Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development 109:911, 1990[Abstract/Free Full Text]
17. Matsui Y, Zsebo KM, Hogan BLM: Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 347:667, 1990[Medline] [Order article via Infotrieve]
18. Keshet E, Lyman SD, Williams DE, Anderson DM, Jenkins NA, Copeland NG, Parada LF: Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J 10:2425, 1991[Medline] [Order article via Infotrieve]
19. Palacios R, Nishikawa S-I: Developmentally regulated cell surface expression and function of c-kit receptor during lymphocyte ontogeny in the embryo and adult mice. Development 115:1133, 1992[Abstract]
20. Motro B, Wojtowicz JM, Bernstein A, van der Kooy D: Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. Proc Natl Acad Sci USA 93:1808, 1996[Abstract/Free Full Text]
21. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S-I, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S-I: Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174:63, 1991[Abstract/Free Full Text]
22. Heinrich MC, Dooley DC, Freed AC, Band L, Hoatlin ME, Keeble WW, Peters ST, Silvey KV, Ey FS, Kabat D, Maziarz RT, Bagby GC Jr: Constitutive expression of steel factor gene by human stromal cells. Blood 82:771, 1993[Abstract/Free Full Text]
23. Linenberger ML, Jacobsen FW, Bennett LG, Broudy VC, Martin FH, Abkowitz JL: Stem cell factor production by human marrow stromal fibroblasts. Exp Hematol 23:1104, 1995[Medline] [Order article via Infotrieve]
24. Broudy VC, Lin NL, Priestley GV, Nocka K, Wolf NS: Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen. Blood 88:75, 1996[Abstract/Free Full Text]
25. Yoshinaga K, Nishikawa S, Ogawa M, Hayashi S-I, Kunisada T, Fujimoto T, Nishikawa S-I: Role of c-kit in mouse spermatogenesis: Identification of spermatogonia as a specific site of c-kit expression and function. Development 113:689, 1991[Abstract]
26. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, Era T, Sakakura T, Nishikawa S: In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: Two distinct waves of c-kit-dependency during melanocyte development. EMBO J 10:2111, 1991[Medline] [Order article via Infotrieve]
27. Donaldson LE, Schmitt E, Huntley JF, Newlands GFJ, Grencis RK: A critical role for stem cell factor and c-kit in host protective immunity to an intestinal helminth. Int Immunol 8:559, 1996[Abstract/Free Full Text]
28. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE: Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175, 1990[Medline] [Order article via Infotrieve]
29. Anderson DM, Williams DE, Tushinski R, Gimpel S, Eisenman J, Cannizzaro LA, Aronson M, Croce CM, Huebner K, Cosman D, Lyman SD: Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ 2:373, 1991[Abstract]
30. Geissler EN, Liao M, Brook JD, Martin FH, Zsebo KM, Housman DE, Galli SJ: Stem cell factor (SCF ), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. Somatic Cell Mol Genet 17:207, 1991[Medline] [Order article via Infotrieve]
31. Galli SJ, Zsebo KM, Geissler EN: The kit ligand, stem cell factor. Adv Immunol 55:1, 1994[Medline] [Order article via Infotrieve]
32. Huang EJ, Nocka KH, Buck J, Besmer P: Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 3:349, 1992[Abstract]
33. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams DE: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63:235, 1990[Medline] [Order article via Infotrieve]
34. Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV, Martin FH, Williams DA: Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 89:7350, 1992[Abstract/Free Full Text]
35. Huang EJ, Manova K, Packer AI, Sanchez S, Bachvarova RF, Besmer P: The murine steel panda mutation affects kit ligand expression and growth of early ovarian follicles. Dev Biol 157:100, 1993[Medline] [Order article via Infotrieve]
36. Marziali G, Lazzaro D, Sorrentino V: Binding of germ cells to mutant Sl^d Sertoli cells is defective and is rescued by expression of the transmembrane form of the c-kit ligand. Dev Biol 157:182, 1993[Medline] [Order article via Infotrieve]
37. Majumdar MK, Feng L, Medlock E, Toksoz D, Williams DA: Identification and mutation of primary and secondary proteolytic cleavage sites in murine stem cell factor cDNA yields biologically active, cell-associated protein. J Biol Chem 269:1237, 1994[Abstract/Free Full Text]
38. Pandiella A, Bosenberg MW, Huang EJ, Besmer P, Massagué J: Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. J Biol Chem 267:24028, 1992[Abstract/Free Full Text]
39. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massagué J: Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271:11376, 1996[Abstract/Free Full Text]
40. Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG: Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83:2145, 1994[Abstract/Free Full Text]
41. Longley BJ Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R: Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328:1302, 1993[Abstract/Free Full Text]
42. Klimpel GR, Chopra AK, Langley KE, Wypych J, Annable CA, Kaiserlian D, Ernst PB, Peterson JW: A role for stem cell factor and c-kit in the murine intestinal tract secretory response to cholera toxin. J Exp Med 182:1931, 1995[Abstract/Free Full Text]
43. Klimpel GR, Langley KE, Wypych J, Abrams JS, Chopra AK, Niesel DW: A role for stem cell factor (SCF ): c-kit interaction(s) in the intestinal tract response to Salmonella typhimurium infection. J Exp Med 184:271, 1996[Abstract/Free Full Text]
44. deCastro CM, Denning SM, Langdon S, Vandenbark GR, Kurtzberg J, Scearce R, Haynes BF, Kaufman RE: The c-kit proto-oncogene receptor is expressed on a subset of human CD3^-CD4^-CD8^- (triple-negative) thymocytes. Exp Hematol 22:1025, 1994[Medline] [Order article via Infotrieve]
45. Tajima Y, Onoue H, Kitamura Y, Nishimune Y: Biologically active kit ligand growth factor is produced by mouse Sertoli cells and is defective in Sl^d mutant mice. Development 113:1031, 1991[Abstract]
46. Manova K, Huang EJ, Angeles M, De Leon V, Sanchez S, Pronovost SM, Besmer P, Bachvarova RF: The expression pattern of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia. Development 157:85, 1993
47. Manova K, Bachvarova RF, Huang EJ, Sanchez S, Pronovost SM, Velazquez E, McGuire B, Besmer P: c-kit receptor and ligand expression in postnatal development of the mouse cerebellum suggests a function for c-kit in inhibitory interneurons. J Neurosci 12:4663, 1992[Abstract]
48. Ratajczak MZ, Kuczynski WI, Sokol DL, Moore JS, Pletcher CH Jr, Gewirtz AM: Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34⁺, c-Kit⁺ marrow cells. Blood 86:2161, 1995[Abstract/Free Full Text]
49. Broudy VC, Kaushansky K, Harlan JM, Adamson JW: Interleukin-1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol 139:464, 1987[Abstract]
50. Heinrich MC, Dooley DC, Keeble WW: Transforming growth factor 1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood 85:1769, 1995[Abstract/Free Full Text]
51. Langley KE, Bennett LG, Wypych J, Yancik SA, Liu X-D, Westcott KR, Chang DG, Smith KA, Zsebo KM: Soluble stem cell factor in human serum. Blood 81:656, 1993[Abstract/Free Full Text]
52. Wodnar-Filipowicz A, Yancik S, Moser Y, dalle Carbonare V, Gratwohl A, Tichelli A, Speck B, Nissen C: Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood 81:3259, 1993[Abstract/Free Full Text]
53. Bowen D, Yancik S, Bennett L, Culligan D, Resser K: Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 85:63, 1993[Medline] [Order article via Infotrieve]
54. Abkowitz JL, Hume H, Yancik SA, Bennett LG, Matsumoto AM: Stem cell factor serum levels may not be clinically relevant. Blood 87:4017, 1996[Free Full Text]
55. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Panici PB, Pierelli L, Menichella G, Leone G, Mancuso S, Peschle C: Autologous stem cell transplantation: Release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood 84:3532, 1994[Abstract/Free Full Text]
56. Hunt P, Zsebo KM, Hokom MM, Hornkohl A, Birkett NC, del Castillo JC, Martin F: Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-Fluorouracil treatment. Blood 80:904, 1992[Abstract/Free Full Text]
57. Limmani A, Baker WH, Chang CM, Seemann R, Williams DE, Patchen ML: c-kit ligand gene expression in normal and sublethally irradiated mice. Blood 85:2377, 1995[Abstract/Free Full Text]
58. Arakawa T, Yphantis DA, Lary JW, Narhi LO, Lu HS, Prestrelski SJ, Clogston CL, Zsebo KM, Mendiaz EA, Wypych J, Langley KE: Glycosylated and unglycosylated recombinant-derived human stem cell factors are dimeric and have extensive regular secondary structure. J Biol Chem 266:18942, 1991[Abstract/Free Full Text]
59. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, Satyagal VN, Tung W, Bosselman RA, Mendiaz EA, Langley KE: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63:195, 1990[Medline] [Order article via Infotrieve]
60. Lu HS, Clogston CL, Wypych J, Fausset PR, Lauren S, Mendiaz EA, Zsebo KM, Langley KE: Amino acid sequence and post-translational modification of stem cell factor isolated from Buffalo rat liver cell-conditioned medium. J Biol Chem 266:8102, 1991[Abstract/Free Full Text]
61. Lu HS, Clogston CL, Wypych J, Parker VP, Lee TD, Swiderek K, Baltera RF Jr, Patel AC, Chang DC, Brankow DW, Liu X-D, Ogden SG, Karkare SB, Hu SS, Zsebo KM, Langley KE: Post-translational processing of membrane-associated recombinant human stem cell factor expressed in Chinese hamster ovary cells. Arch Biochem Biophys 298:150, 1992[Medline] [Order article via Infotrieve]
62. Langley KE, Wypych J, Mendiaz EA, Clogston CL, Parker VP, Farrar DH, Brothers MO, Satygal VN, Leslie I, Birkett NC, Smith KA, Baltera RF Jr, Lyons DE, Hogan JM, Crandall C, Boone TC, Pope JA, Karkare SB, Zsebo KM, Sachdev RK, Lu HS: Purification and characterization of soluble forms of human and rat stem cell factor recombinantly expressed by Escherichia coli and by Chinese hamster ovary cells. Arch Biochem Biophys 295:21, 1992[Medline] [Order article via Infotrieve]
63. Nishikawa M, Tojo A, Ikebuchi K, Katayama K, Fujii N, Ozawa K, Asano S: Deletion mutagenesis of stem cell factor defines the c-terminal sequences essential for its biological activity. Biochem Biophys Res Commun 188:292, 1992[Medline] [Order article via Infotrieve]
64. Jones MD, Narhi LO, Chang W-C, Lu HS: Refolding and oxidation of recombinant human stem cell factor produced in Escherichia coli. J Biol Chem 271:11301, 1996[Abstract/Free Full Text]
65. Lu HS, Jones MD, Shieh J-H, Mendiaz EA, Feng D, Watler P, Narhi LO, Langley KE: Isolation and characterization of a disulfide-linked human stem cell factor dimer. J Biol Chem 271:11309, 1996[Abstract/Free Full Text]
66. Bazan JF: Genetic and structural homology of stem cell factor and macrophage colony-stimulating factor. Cell 65:9, 1991[Medline] [Order article via Infotrieve]
67. Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341, 1987[Medline] [Order article via Infotrieve]
68. Qiu F, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P: Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7:1003, 1988[Medline] [Order article via Infotrieve]
69. Pandit J, Bohm A, Jancarik J, Halenbeck R, Koths K, Kim S-H: Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. Science 258:1358, 1992[Abstract/Free Full Text]
70. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, Birkett NC, Smith KA, Johnson MJ, Parker VP, Flores JC, Patel AC, Fisher EF, Erjavec HO, Herrera CJ, Wypych J, Sachdev RK, Pope JA, Leslie I, Wen D, Lin C-H, Cupples RL, Zsebo KM: Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203, 1990[Medline] [Order article via Infotrieve]
71. Lev S, Yarden Y, Givol D: Dimerization and activation of the Kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem 267:15970, 1992[Abstract/Free Full Text]
72. Matous JV, Langley K, Kaushansky K: Structure-function relationships of stem cell factor: An analysis based on a series of human-murine stem cell factor chimera and the mapping of a neutralizing monoclonal antibody. Blood 88:437, 1996[Abstract/Free Full Text]
73. Brannan CI, Bedell MA, Resnick JL, Eppig JJ, Handel MA, Williams DE, Lyman SD, Donovan PJ, Jenkins NA, Copeland NG: Developmental abnormalities in Steel^17H mice result from a splicing defect in the steel factor cytoplasmic tail. Genes Dev 6:1832, 1992[Abstract/Free Full Text]
74. Langley KE, Mendiaz EA, Liu N, Narhi LO, Zeni L, Parseghian CM, Clogston CL, Leslie I, Pope JA, Lu HS, Zsebo KM: Properties of variant forms of human stem cell factor recombinantly expressed in Escherchia coli. Arch Biochem Biophys 311:55, 1994[Medline] [Order article via Infotrieve]
75. Russell ES, Bernstein SE, Lawson FA, Smith LJ: Long-continued function of normal blood-forming tissue transplanted into genetically anemic hosts. J Natl Cancer Inst 23:557, 1959
76. Dexter TM, Moore MAS: In vitro duplication and `cure' of haemopoietic defects in genetically anaemic mice. Nature 269:412, 1977[Medline] [Order article via Infotrieve]
77. Bernstein SE: Tissue transplantation as an analytic and therapeutic tool in hereditary anemias. Am J Surg 119:448, 1970[Medline] [Order article via Infotrieve]
78. Wolf NS: Dissecting the hematopoietic microenvironment. III. Evidence for a short range stimulus for cellular proliferation. Cell Tissue Kinet 11:335, 1978[Medline] [Order article via Infotrieve]
79. McCulloch EA, Siminovitch L, Till JE: Spleen-colony formation in anemic mice of genotype WW^V. Science 144:844, 1964[Abstract/Free Full Text]
80. Lewis JP, O'Grady LF, Bernstein SE, Russell ES, Trobaugh FE Jr: Growth and differentiation of transplanted W/W^v marrow. Blood 30:601, 1967[Abstract/Free Full Text]
81. Iscove NN: Committed erythroid precursor populations in genetically anemic W/W^v and Sl/Sl^d mice, in Hibino S, Takaku F, Shahidi NT (eds): Aplastic Anemia. Baltimore, MD, University Park, 1978
82. Gregory CJ, Eaves AC: Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood 51:527, 1978[Abstract/Free Full Text]
83. Barker JE: Sl/Sl^d hematopoietic progenitors are deficient in situ. Exp Hematol 22:174, 1994[Medline] [Order article via Infotrieve]
84. Leary AG, Zeng HQ, Clark SC, Ogawa M: Growth factor requirements for survival in G₀ and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci USA 89:4013, 1992[Abstract/Free Full Text]
85. Li CL, Johnson GR: Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. Blood 84:408, 1994[Abstract/Free Full Text]
86. Rebel VI, Dragowska W, Eaves CJ, Humphries RK, Lansdorp PM: Amplification of Sca-1⁺ Lin^- WGA⁺ cells in serum-free cultures containing Steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential. Blood 83:128, 1994[Abstract/Free Full Text]
87. Wineman JP, Nishikawa S-I, Müller-Sieburg CE: Maintenance of high levels of pluripotent hematopoietic stem cells in vitro: Effect of stromal cells and c-kit. Blood 81:365, 1993[Abstract/Free Full Text]
88. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ: Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 87:30, 1996[Abstract/Free Full Text]
89. Hirayama F, Clark SC, Ogawa M: Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 $alpha$ . Proc Natl Acad Sci USA 91:469, 1994[Abstract/Free Full Text]
90. Hirayama F, Ogawa M: Negative regulation of early T lymphopoiesis by interleukin-3 and interleukin-1 $alpha$ . Blood 86:4527, 1995[Abstract/Free Full Text]
91. Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M: Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci USA 93:4040, 1996[Abstract/Free Full Text]
92. Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ, Pragnell IB: Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood 87:4589, 1996[Abstract/Free Full Text]
93. Miller CL, Rebel VI Helgason CD, Lansdorp PM, Eaves CJ: Impaired steel factor responsiveness differentially affects the detection and long-term maintenance of fetal liver hematopoietic stem cells in vivo. Blood 89:1214, 1997[Abstract/Free Full Text]
94. de Vries P, Brasel KA, Eisenman JR, Alpert AR, Williams DE: The effect of recombinant mast cell growth factor on purified murine hematopoietic stem cells. J Exp Med 173:1205, 1991[Abstract/Free Full Text]
95. Kodama H, Nose M, Yamaguchi Y, Tsunoda J, Suda T, Nishikawa S, Nishikawa S: In vitro proliferation of primitive hemopoietic stem cells supported by stromal cells: Evidence for the presence of a mechanism(s) other than that involving c-kit receptor and its ligand. J Exp Med 176:351, 1992[Abstract/Free Full Text]
96. Sutherland HJ, Hogge DE, Cook D, Eaves CJ: Alternative mechanisms with and without steel factor support primitive human hematopoiesis. Blood 81:1465, 1993[Abstract/Free Full Text]
97. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ: Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 93:1470, 1996[Abstract/Free Full Text]
98. Bernstein ID, Andrews RG, Zsebo KM: Recombinant human stem cell factor enhances the formation of colonies by CD34⁺ and CD34⁺lin^- cells, and the generation of colony-forming cell progeny from CD34⁺lin^- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 77:2316, 1991[Abstract/Free Full Text]
99. Migliaccio G, Migliaccio AR, Druzin ML, Giardina P-JV, Zsebo KM, Adamson JW: Long-term generation of colony-forming cells in liquid culture of CD34⁺ cord blood cells in the presence of recombinant human stem cell factor. Blood 79:2620, 1992[Abstract/Free Full Text]
100. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ: Ex vivo expansion and maturation of peripheral blood CD34⁺ cells into the myeloid lineage. Blood 80:1405, 1992[Abstract/Free Full Text]
101. Brandt J, Briddell RA, Srour EF, Leemhuis TB, Hoffman R: Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. Blood 79:634, 1992[Abstract/Free Full Text]
102. Brugger W, Möcklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Ex vivo expansion of enriched peripheral blood CD34⁺ progenitor cells by stem cell factor, interleukin-1 $beta$ (IL-1 $beta$ ), IL-6, IL-3, interferon- $gamma$ , and erythropoietin. Blood 81:2579, 1993[Abstract/Free Full Text]
103. Henschler R, Brugger W, Luft T, Frey T, Mertelsmann R, Kanz L: Maintenance of transplantation potential in ex vivo expanded CD34⁺-selected human peripheral blood progenitor cells. Blood 84:2898, 1994[Abstract/Free Full Text]
104. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283, 1995[Abstract/Free Full Text]
105. Sato N, Sawada K, Koizumi K, Tarumi T, Ieko M, Yasukouchi T, Yamaguchi M, Takahashi TA, Sekiguchi S, Koike T: In vitro expansion of human peripheral blood CD34⁺ cells. Blood 82:3600, 1993[Abstract/Free Full Text]
106. Shapiro F, Yao T-J, Raptis G, Reich L, Norton L, Moore MAS: Optimization of conditions for ex vivo expansion of CD34⁺ cells from patients with stage IV breast cancer. Blood 84:3567, 1994[Abstract/Free Full Text]
107. Sui X, Tsuji K, Tanaka R, Tajima S, Muraoka K, Ebihara Y, Ikebuchi K, Yasukawa K, Taga T, Kishimoto T, Nakahata T: gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci USA 92:2859, 1995[Abstract/Free Full Text]
108. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M: Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 88:429, 1996[Abstract/Free Full Text]
109. Nocka K, Buck J, Levi E, Besmer P: Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 9:3287, 1990[Medline] [Order article via Infotrieve]
110. Broxmeyer HE, Hangoc G, Cooper S, Anderson D, Cosman D, Lyman SD, Williams DE: Influence of murine mast cell growth factor (c-kit ligand) on colony formation by mouse marrow hematopoietic progenitor cells. Exp Hematol 19:143, 1991[Medline] [Order article via Infotrieve]
111. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19:226, 1991[Medline] [Order article via Infotrieve]
112. Broxmeyer HE, Cooper S, Lu L, Hangoc G, Anderson D, Cosman D, Lyman SD, Williams DE: Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 77:2142, 1991[Abstract/Free Full Text]
113. Migliaccio G, Migliaccio AR, Druzin ML, Giardina P-JV, Zsebo KM, Adamson JW: Effects of recombinant human stem cell factor (SCF ) on the growth of human progenitor cells in vitro. J Cell Physiol 148:503, 1991[Medline] [Order article via Infotrieve]
114. Metcalf D, Nicola NA: Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: Effects of combination with colony-stimulating factors. Proc Natl Acad Sci USA 88:6239, 1991[Abstract/Free Full Text]
115. Lemoli RM, Fortuna A, Fogli M, Motta MR, Rizzi S, Benini C, Tura S: Stem cell factor (c-kit ligand) enhances the interleukin-9-dependent proliferation of human CD34⁺ and CD34⁺CD33^-DR^- cells. Exp Hematol 22:919, 1994[Medline] [Order article via Infotrieve]
116. Fahlman C, Blomhoff HK, Veiby OP, McNiece IK, Jacobsen SEW: Stem cell factor and interleukin-7 synergize to enhance early myelopoiesis in vitro. Blood 84:1450, 1994[Abstract/Free Full Text]
117. Keller JR, Ortiz M, Ruscetti FW: Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. Blood 86:1757, 1995[Abstract/Free Full Text]
118. Dai CH, Krantz SB, Zsebo KM: Human burst-forming units-erythroid need direct interaction with stem cell factor for further development. Blood 78:2493, 1991[Abstract/Free Full Text]
119. Papayannopoulou T, Brice M, Blau CA: Kit ligand in synergy with interleukin-3 amplifies the erythropoietin-independent, globin-synthesizing progeny of normal human burst-forming units-erythroid in suspension cultures: Physiologic implications. Blood 81:299, 1993[Abstract/Free Full Text]
120. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Besmer P: Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev 3:816, 1989[Abstract/Free Full Text]
121. de Wolf JTM, Muller EW, Hendriks DH, Halie RM, Vellenga E: Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood associated with ongoing differentiation. Blood 84:59, 1994[Abstract/Free Full Text]
122. Muta K, Krantz SB, Bondurant MC, Wickrema A: Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 94:34, 1994
123. Wu H, Klingmüller U, Besmer P, Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377:242, 1995[Medline] [Order article via Infotrieve]
124. Wu H, Klingmüller U, Acurio A, Hsiao JG, Lodish HF: Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci USA 94:1806, 1997[Abstract/Free Full Text]
125. Sui X, Tsuji K, Tajima S, Tanaka R, Muraoka K, Ebihara Y, Ikebuchi K, Yasukawa K, Taga T, Kishimoto T, Nakahata T: Erythropoietin-independent erythrocyte production: Signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34⁺ cells. J Exp Med 183:837, 1996[Abstract/Free Full Text]
126. Peschle C, Gabbianelli M, Testa U, Pelosi E, Barberi T, Fossati C, Valtieri M, Leone L: c-kit ligand reactivates fetal hemoglobin synthesis in serum-free culture of stringently purified normal adult burst-forming unit-erythroid. Blood 81:328, 1993[Abstract/Free Full Text]
127. Muta K, Krantz SB, Bondurant MC, Dai C-H: Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood 86:572, 1995[Abstract/Free Full Text]
128. Okumura N, Tsuji K, Ebihara Y, Tanaka I, Sawai N, Koike K, Komiyama A, Nakahata T: Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells. Blood 87:4100, 1996[Abstract/Free Full Text]
129. Broudy VC, Lin NL, Kaushansky K: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719, 1995[Abstract/Free Full Text]
130. Briddell RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R: Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 78:2854, 1991[Abstract/Free Full Text]
131. Avraham H, Vannier E, Cowley S, Jiang S, Chi S, Dinarello CA, Zsebo KM, Groopman JE: Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 79:365, 1992[Abstract/Free Full Text]
132. Debili N, Massé J-M, Katz A, Guichard J, Breton-Gorius J, Vainchenker W: Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34⁺ cells. Blood 82:84, 1993[Abstract/Free Full Text]
133. Grabarek J, Groopman JE, Lyles YR, Jiang S, Bennett L, Zsebo K, Avraham H: Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 269:21718, 1994[Abstract/Free Full Text]
134. Kitamura Y, Go S, Hatanaka K: Decrease of mast cells in W/W^v mice and their increase by bone marrow transplantation. Blood 52:447, 1978[Abstract/Free Full Text]
135. Kitamura Y, Go S: Decreased production of mast cells in Sl/Sl^d anemic mice. Blood 53:492, 1979[Free Full Text]
136. Suda T, Suda J, Spicer SS, Ogawa M: Proliferation and differentiation in culture of mast cell progenitors derived from mast cell-deficient mice of genotype W/W^v. J Cell Physiol 122:187, 1985[Medline] [Order article via Infotrieve]
137. Jarboe DL, Huff TF: The mast cell-committed progenitor: W/W^v mice do not make mast cell-committed progenitors and Sl/Sl^d fibroblasts do not support development of normal mast cell-committed progenitors. J Immunol 142:2418, 1989[Abstract]
138. Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ: Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA 88:6382, 1991[Abstract/Free Full Text]
139. Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ: The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144:321, 1994[Abstract]
140. Rodewald H-R, Dessing M, Dvorak AM, Galli SJ: Identification of a committed precursor for the mast cell lineage. Science 271:818, 1996[Abstract]
141. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD: Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34⁺ pluripotent progenitor cells. J Immunol 148:772, 1992[Abstract]
142. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K: Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237, 1992[Abstract/Free Full Text]
143. Durand B, Migliaccio G, Yee NS, Eddleman K, Huima-Byron T, Migliaccio AR, Adamson JW: Long-term generation of human mast cells in serum-free cultures of CD34⁺ cord blood cells stimulated with stem cell factor and interleukin-3. Blood 84:3667, 1994[Abstract/Free Full Text]
144. Irani A-MA, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB: Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009, 1992[Abstract/Free Full Text]
145. Haig DM, Huntley JF, MacKellar A, Newlands GFJ, Inglis L, Sangha R, Cohen D, Hapel A, Galli SJ, Miller HRP: Effects of stem cell factor (Kit-ligand) and interleukin-3 on the growth and serine proteinase expression of rat bone marrow-derived or serosal mast cells. Blood 83:72, 1994[Abstract/Free Full Text]
146. Rennick D, Hunte B, Holland G, Thompson-Snipes L: Cofactors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: Comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts. Blood 85:57, 1995[Abstract/Free Full Text]
147. Wershil BK, Tsai M, Geissler EN, Zsebo KM, Galli SJ: The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. evidence that signaling through the c-kit receptor can induce expression of cellular function. J Exp Med 175:245, 1992[Abstract/Free Full Text]
148. Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM: The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 149:599, 1992[Abstract]
149. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR: The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79:958, 1992[Abstract/Free Full Text]
150. Dastych J, Metcalfe DD: Stem cell factor induces mast cell adhesion to fibronectin. J Immunol 152:213, 1994[Abstract]
151. Bischoff SC, Dahinden CA: c-kit ligand: A unique potentiator of mediator release by human lung mast cells. J Exp Med 175:237, 1992[Abstract/Free Full Text]
152. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ: Differential release of mast cell interleukin-6 via c-kit. Blood 89:2654, 1997[Abstract/Free Full Text]
153. Galli SJ, Iemura A, Garlick DS, Gamba-Vitalo C, Zsebo KM, Andrews RG: Reversible expansion of primate mast cell populations in vivo by stem cell factor. J Clin Invest 91:148, 1993
154. Tsai M, Shih L-S, Newlands GFJ, Takeishi T, Langley KE, Zsebo KM, Miller HRP, Geissler EN, Galli SJ: The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med 174:125, 1991[Abstract/Free Full Text]
155. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ: Recombinant human stem cell factor (Kit ligand) promotes human mast cell and melanocyte hyperplasia and funcational activation in vivo. J Exp Med 183:2681, 1996[Abstract/Free Full Text]
156. Opstelten D, Osmond DG: Regulation of pre-B cell proliferation in bone marrow: Immunofluorescence stathmokinetic studies of cytoplasmic µ chain-bearing cells in anti-IgM-treated mice, hematologically deficient mutant mice and mice given sheep red blood cells. Eur J Immunol 15:599, 1985[Medline] [Order article via Infotrieve]
157. Landreth KS, Kincade PW, Lee G, Harrison DE: B lymphocyte precursors in embryonic and adult W anemic mice. J Immunol 132:2724, 1984[Abstract]
158. Rico-Vargas SA, Weiskopf B, Nishikawa S-I, Osmond DG: c-kit expression by B cell precursors in mouse bone marrow. J Immunol 152:2845, 1994[Abstract]
159. Takeda S, Shimizu S, Rodewald H-R: Interactions between c-kit and stem cell factor are not required for B-cell development in vivo. Blood 89:518, 1997[Abstract/Free Full Text]
160. Rolink A, Melchers F: Molecular and cellular origins of B lymphocyte diversity. Cell 66:1081, 1991[Medline] [Order article via Infotrieve]
161. Hirayama F, Shih J-P, Awgulewitsch A, Warr GW, Clark SC, Ogawa M: Clonal proliferation of murine lymphohemopoietic progenitors in culture. Proc Natl Acad Sci USA 89:5907, 1992[Abstract/Free Full Text]
162. Veiby OP, Lyman SD, Jacobsen SEW: Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Blood 88:1256, 1996[Abstract/Free Full Text]
163. Faust EA, Saffran DC, Toksoz D, Williams DA, Witte ON: Distinctive growth requirements and gene expression patterns distinguish progenitor B cells from pre-B cells. J Exp Med 177:915, 1993[Abstract/Free Full Text]
164. Billips LG, Petitte D, Dorshkind K, Narayanan R, Chiu C-P, Landreth KS: Differential roles of stromal cells, interleukin-7, and kit-ligand in the regulation of B lymphopoiesis. Blood 79:1185, 1992[Abstract/Free Full Text]
165. Rolink A, Streb M, Nishikawa S-I, Melchers F: The c-kit-encoded tyrosine kinase regulates the proliferation of early pre-B cells. Eur J Immunol 21:2609, 1991[Medline] [Order article via Infotrieve]
166. Rodewald H-R, Kretzschmar K, Swat W, Takeda S: Intrathymically expressed c-kit ligand (stem cell factor) is a major factor driving expansion of very immature thymocytes in vivo. Immunity 3:313, 1995[Medline] [Order article via Infotrieve]
167. Godfrey DI, Zlotnik A, Suda T: Phenotypic and functional characterization of c-kit expression during intrathymic T cell development. J Immunol 149:2281, 1992[Abstract]
168. Laky K, Lefrancois L, Puddington L: Age-dependent intestinal lymphoproliferative disorder due to stem cell factor receptor deficiency. J Immunol 158:1417, 1997[Abstract]
169. Bluman EM, Schnier GS, Avalos BR, Strout MP, Sultan H, Jacobson FW, Williams DE, Carson WE, Caligiuri MA: The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood 88:3887, 1996[Abstract/Free Full Text]
170. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H: Lymphokine requirement for the generation of natural killer cells from CD34⁺ hematopoietic progenitor cells. Blood 85:3538, 1995[Abstract/Free Full Text]
171. Matos ME, Schnier GS, Beecher MS, Ashman LK, Williams DE, Caligiuri MA: Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 178:1079, 1993[Abstract/Free Full Text]
172. Young JW, Szabolcs P, Moore MAS: Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor $alpha$ . J Exp Med 182:1111, 1995[Abstract/Free Full Text]
173. Szabolcs P, Moore MAS, Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone maarrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF- $alpha$ . J Immunol 154:5851, 1995[Abstract]
174. Yoder MC, Williams DA: Matrix molecule interactions with hematopoietic stem cells. Exp Hematol 23:961, 1995[Medline] [Order article via Infotrieve]
175. Rosemblatt M, Vuillet-Gaugler MH, Leroy C, Coulombel L: Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature human erythroblastic precursor cells. J Clin Invest 87:6, 1991
176. Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM: Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 80:388, 1992[Abstract/Free Full Text]
177. Verfaillie CM, McCarthy JB, McGlave PB: Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174:693, 1991[Abstract/Free Full Text]
178. Williams DA, Rios M, Stephens C, Patel VP: Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352:438, 1991[Medline] [Order article via Infotrieve]
179. Vuillet-Gaugler MH, Breton-Gorius J, Vainchenker W, Guichard J, Leroy C, Tchernia G, Coulombel L: Loss of attachment to fibronectin with terminal human erythroid differentiation. Blood 75:865, 1990[Abstract/Free Full Text]
180. Hurley RW, McCarthy JB, Verfaillie CM: Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 96:511, 1995
181. Healy L, May G, Gale K, Grosveld F, Greaves M, Enver T: The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc Natl Acad Sci USA 92:12240, 1995[Abstract/Free Full Text]
182. Kinashi T, Springer TA: Steel factor and c-kit regulate cell-matrix adhesion. Blood 83:1033, 1994[Abstract/Free Full Text]
183. Kaneko Y, Takenawa J, Yoshida O, Fujita K, Sugimoto K, Nakayama H, Fujita J: Adhesion of mouse mast cells to fibroblasts: Adverse effects of steel (Sl) mutation. J Cell Physiol 147:224, 1991[Medline] [Order article via Infotrieve]
184. Adachi S, Ebi Y, Nishikawa S, Hayashi S, Yamazaki M, Kasugai T, Yamamura T, Nomura S, Kitamura Y: Necessity of extracellular domain of W (c-kit) receptors for attachment of murine cultured mast cells to fibroblasts. Blood 79:650, 1992[Abstract/Free Full Text]
185. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P: Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 14:473, 1995[Medline] [Order article via Infotrieve]
186. Kovach NL, Lin N, Yednock T, Harlan JM, Broudy VC: Stem cell factor modulates avidity of $alpha$ ₄ $beta$ ₁ and $alpha$ ₅ $beta$ ₁ integrins expressed on hematopoietic cell lines. Blood 85:159, 1995[Abstract/Free Full Text]
187. Lévesque J-P, Leavesley DI, Niutta S, Vadas M, Simmons PJ: Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 181:1805, 1995[Abstract/Free Full Text]
188. Lévesque J-P, Haylock DN, Simmons PJ: Cytokine regulation of proliferation and cell adhesion are correlated events in human CD34⁺ hemopoietic progenitors. Blood 88:1168, 1996[Abstract/Free Full Text]
189. Kodama H, Nose M, Niida S, Nishikawa S, Nishikawa S-I: Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. Exp Hematol 22:979, 1994[Medline] [Order article via Infotrieve]
190. Avraham H, Scadden DT, Chi S, Broudy VC, Zsebo KM, Groopman JE: Interaction of human bone marrow fibroblasts with megakaryocytes: Role of the c-kit ligand. Blood 80:1679, 1992[Abstract/Free Full Text]
191. Takahira H, Gotoh A, Ritchie A, Broxmeyer HE: Steel factor enhances integrin-mediated tyrosine phosphorylation of focal adhesion kinase (pp125^FAK) and paxillin. Blood 89:1574, 1997[Abstract/Free Full Text]
192. Anklesaria P, Greenberger J, Pratt DBC, Fitzgerald TJ, Sullenbarger B, Campbell A, Williams D, Wicha M: Steel factor induces a marrow specific adhesion protein hemonectin in stromal cell lines from Sl/Sl^d mice. Exp Hematol 20:807, 1992 (abstr)
193. Anklesaria P, Greenberger JS, Fitzgerald TJ, Sullenbarger B, Wicha M, Campbell A: Hemonectin mediates adhesion of engrafted murine progenitors to a clonal bone marrow stromal cell line from Sl/Sl^d mice. Blood 77:1691, 1991[Abstract/Free Full Text]
194. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin C-H: Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 10:4121, 1991[Medline] [Order article via Infotrieve]
195. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL: Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc Natl Acad Sci USA 90:3760, 1993[Abstract/Free Full Text]
196. Yan X-Q, Briddell R, Hartley C, Stoney G, Samal B, McNiece I: Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 84:795, 1994[Abstract/Free Full Text]
197. Andrews RG, Bartelmez SH, Knitter GH, Myerson D, Bernstein ID, Appelbaum FR, Zsebo KM: A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34⁺ colony-forming cell types in blood and marrow of baboons. Blood 80:920, 1992[Abstract/Free Full Text]
198. Andrews RG, Bensinger WI, Knitter GH, Bartelmez SH, Longin K, Bernstein ID, Appelbaum FR, Zsebo KM: The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. Blood 80:2715, 1992[Abstract/Free Full Text]
199. Papayannopoulou T, Nakamoto B: Peripheralization of hemopoietic progenitors in primates treated with anti-VLA₄ integrin. Proc Natl Acad Sci USA 90:9374, 1993[Abstract/Free Full Text]
200. Papayannopoulou T, Craddock C, Nakamoto B, Priestley G, Wolf NS: The VLA₄/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 92:9647, 1995[Abstract/Free Full Text]
201. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 84:2068, 1994[Abstract/Free Full Text]
202. Tong J, Gordon MS, Srour EF, Cooper RJ, Orazi A, McNiece I, Hoffman R: In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood 82:784, 1993[Abstract/Free Full Text]
203. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323, 1996[Abstract/Free Full Text]
204. Bodine DM, Orlic D, Birkett NC, Seidel NE, Zsebo KM: Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sl^d mice as a single factor. Blood 79:913, 1992[Abstract/Free Full Text]
205. Molineux G, Migdalska A, Szmitkowski M, Zsebo K, Dexter TM: The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood 78:961, 1991[Abstract/Free Full Text]
206. Bodine DM, Seidel NE, Zsebo KM, Orlic D: In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells. Blood 82:445, 1993[Abstract/Free Full Text]
207. Harrison DE, Zsebo KM, Astle CM: Splenic primitive hematopoietic stem cell (PHSC) activity is enhanced by steel factor because of PHSC proliferation. Blood 83:3146, 1994[Abstract/Free Full Text]
208. Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D: Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 84:1482, 1994[Abstract/Free Full Text]
209. Dunbar CE, Seidel NE, Doren S, Sellers S, Cline AP, Metzger ME, Agricola BA, Donahue RE, Bodine DM: Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 93:11871, 1996[Abstract/Free Full Text]
210. Yan X-Q, Hartley C, McElroy P, Chang A, McCrea C, McNiece I: Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood 85:2303, 1995[Abstract/Free Full Text]
211. Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK: Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 85:15, 1995[Abstract/Free Full Text]
212. Russell ES, Bernstein SE, McFarland EC, Modeen WR: The cellular basis of differential radiosensitivity of normal and genetically anemic mice. Radiat Res 20:677, 1963
213. Yee NS, Paek I, Besmer P: Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: Basis for radiosensitivity of White Spotting and Steel mutant mice. J Exp Med 179:1777, 1994[Abstract/Free Full Text]
214. Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, McNiece IK: Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci USA 89:9464, 1992[Abstract/Free Full Text]
215. Leigh BR, Khan W, Hancock SL, Knox SJ: Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation. Radiat Res 142:12, 1995[Medline] [Order article via Infotrieve]
216. Patchen ML, Fischer R, Schmauder-Chock EA, Williams DE: Mast cell growth factor enhances multilineage hematopoietic recovery in vivo following radiation-induced aplasia. Exp Hematol 22:31, 1994[Medline] [Order article via Infotrieve]
217. Schuening FG, Appelbaum FR, Deeg HJ, Sullivan-Pepe M, Graham TC, Hackman R, Zsebo KM, Storb R: Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 81:20, 1993[Abstract/Free Full Text]
218. Neta R, Williams D, Selzer F, Abrams J: Inhibition of c-kit ligand/steel factor by antibodies reduces survival of lethally irradiated mice. Blood 81:324, 1993[Abstract/Free Full Text]
219. Molineux G, Migdalska A, Haley J, Evans GS, Dexter TM: Total marrow failure induced by pegylated stem-cell factor administered before 5-Fluorouracil. Blood 83:3491, 1994[Abstract/Free Full Text]
220. Du XX Keller D, Maze R, Williams DA: Comparative effects of in vivo treatment using interleukin-11 and stem factor on reconstitution in mice after bone marrow transplantation. Blood 82:1016, 1993[Abstract/Free Full Text]
221. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Graham TC, Schuening FG, Shulman H, Yu C, Bryant E, Burnett R, Seidel K: DLA-identical bone marrow grafts after low-dose total body irradiation. The effect of canine recombinant hematopoietic growth factors. Blood 84:3558, 1994[Abstract/Free Full Text]
222. Dolci S, Williams DE, Ernst MK, Resnick JL, Brannan CI, Lock LF, Lyman SD, Boswell HS, Donovan PJ: Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 352:809, 1991[Medline] [Order article via Infotrieve]
223. Matsui Y, Toksoz D, Nishikawa S, Nishikawa S-I, Williams D, Zsebo K, Hogan BLM: Effect of steel factor and leukaemia inhibitory factor on murine primordial germ cells in culture. Nature 353:750, 1991[Medline] [Order article via Infotrieve]
224. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K: Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85:641, 1995[Abstract/Free Full Text]
225. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179, 1995[Medline] [Order article via Infotrieve]
226. Majumdar MK, Everett ET, Xiao X, Cooper R, Langley K, Kapur R, Vik T, Williams DA: Xenogeneic expression of human stem cell factor in transgenic mice mimics codominant c-kit mutations. Blood 87:3203, 1996[Abstract/Free Full Text]
227. Kapur R, Majumdar MK, Xiao X, Schindler K, McAndrews-Hill M, Williams DA: Transgenic expression of stem cell factor in Steel-dickie mice: Delineation of a unique in vivo role of membrane-associated protein in erythropoiesis. Blood 88:473a, 1996 (abstr, suppl 1)
228. Wehrle-Haller B, Weston JA: Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development 121:731, 1995[Abstract]
229. Besmer P, Murphy JE, George PC, Qiu F, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320:415, 1986[Medline] [Order article via Infotrieve]
230. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203, 1990[Medline] [Order article via Infotrieve]
231. Heldin C-H: Dimerization of cell surface receptors in signal transduction. Cell 80:213, 1995[Medline] [Order article via Infotrieve]
232. Paulson RF, Vesely S, Siminovitch KA, Bernstein A: Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat Genet 13:309, 1996[Medline] [Order article via Infotrieve]
233. Lorenz U, Bergemann AD, Steinberg HN, Flanagan JG, Li X, Galli SJ, Neel BG: Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-kit by the protein tyrosine phosphatase SHP1. J Exp Med 184:1111, 1996[Abstract/Free Full Text]
234. Blechman JM, Lev S, Brizzi MF, Leitner O, Pegoraro L, Givol D, Yarden Y: Soluble c-Kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. J Biol Chem 268:4399, 1993[Abstract/Free Full Text]
235. Lev S, Blechman J, Nishikawa S-I, Givol D, Yarden Y: Interspecies molecular chimeras of Kit help define the binding site of the stem cell factor. Mol Cell Biol 13:2224, 1993[Abstract/Free Full Text]
236. Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y: The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80:103, 1995[Medline] [Order article via Infotrieve]
237. Lev S, Yarden Y, Givol D: A recombinant ectodomain of the receptor for the stem cell factor (SCF ) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. J Biol Chem 267:10866, 1992[Abstract/Free Full Text]
238. Turner AM, Bennett LG, Lin NL, Wypych J, Bartley TD, Hunt RW, Atkins HL, Langley KE, Parker V, Martin F, Broudy VC: Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. Blood 85:2052, 1995[Abstract/Free Full Text]
239. Philo JS, Wen J, Wypych J, Schwartz MG, Mendiaz EA, Langley KE: Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit. J Biol Chem 271:6895, 1996[Abstract/Free Full Text]
240. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A, Pawson T: Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J 10:2451, 1991[Medline] [Order article via Infotrieve]
241. Piao X, Curtis JE, Minkin S, Minden MD, Bernstein A: Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 83:476, 1994[Abstract/Free Full Text]
242. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736, 1993
243. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83:2619, 1994[Abstract/Free Full Text]
244. Hashimoto K, Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, Morimoto M, Kitayama H, Kanakura Y, Kitamura Y: Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol 148:189, 1996[Abstract]
245. Piao X, Bernstein A: A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 87:3117, 1996[Abstract/Free Full Text]
246. Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J, Okabe M, Suzuki M, Yamamura K-i, Matsuzawa Y, Kitamura Y, Kanakura Y: Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88:995, 1996[Abstract/Free Full Text]
247. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560, 1995[Abstract/Free Full Text]
248. Longley BJ, Tyrrell L, Lu S-Z, Ma Y-S, Langley K, Ding T-g, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312, 1996[Medline] [Order article via Infotrieve]
249. Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A: Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93:14665, 1996[Abstract/Free Full Text]
250. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85:790, 1995[Abstract/Free Full Text]
251. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y: Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87:273, 1996[Abstract/Free Full Text]
252. Giebel LB, Spritz RA: Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 88:8696, 1991[Abstract/Free Full Text]
253. Fleischman RA: Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene. J Clin Invest 89:1713, 1992
254. Spritz RA, Giebel LB, Holmes SA: Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 50:261, 1992[Medline] [Order article via Infotrieve]
255. Spritz RA, Holmes SA, Ramesar R, Greenberg J, Curtis D, Beighton P: Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism. Am J Hum Genet 51:1058, 1992[Medline] [Order article via Infotrieve]
256. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Nishikawa S, Miura Y, Suda T: Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood 78:1706, 1991[Abstract/Free Full Text]
257. Doi H, Inaba M, Yamamoto Y, Taketani S, Mori S-I, Sugihara A, Ogata H, Toki J, Hisha H, Inaba K, Sogo S, Adachi M, Matsuda T, Good RA, Ikehara S: Pluripotent hemopoietic stem cells are c-kit^<low. Proc Natl Acad Sci USA 94:2513, 1997[Abstract/Free Full Text]
258. Kawashima I, Zanjani ED, Almaida-Porada G, Flake AW, Zeng H, Ogawa M: CD34⁺ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood 87:4136, 1996[Abstract/Free Full Text]
259. Ikuta K, Weissman IL: Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci USA 89:1502, 1992[Abstract/Free Full Text]
260. Li CL, Johnson GR: Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization. Blood 85:1472, 1995[Abstract/Free Full Text]
261. Jones RJ, Collector MI, Barber JP, Vala MS, Fackler MJ, May WS, Griffin CA, Hawkins AL, Zehnbauer BA, Hilton J, Colvin OM, Sharkis SJ: Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 88:487, 1996[Abstract/Free Full Text]
262. Osawa M, Hanada K, Hamada H, Nakauchi H: Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242, 1996[Abstract]
263. Osawa M, Nakamura K, Nishi N, Takahashi N, Tokuomoto Y, Inoue H, Nakauchi H: In vivo self-renewal of c-kit⁺ Sca-1⁺ Lin^low/^- hemopoietic stem cells. J Immunol 156:3207, 1996[Abstract]
264. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA: Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 78:30, 1991[Abstract/Free Full Text]
265. Broudy VC, Lin N, Zsebo KM, Birkett NC, Smith KA, Bernstein ID, Papayannopoulou T: Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood 79:338, 1992[Abstract/Free Full Text]
266. Papayannopoulou T, Brice M, Broudy VC, Zsebo KM: Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: Functional properties and composite antigenic profile. Blood 78:1403, 1991[Abstract/Free Full Text]
267. Briddell RA, Broudy VC, Bruno E, Brandt JE, Srour EF, Hoffman R: Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor. Blood 79:3159, 1992[Abstract/Free Full Text]
268. De Jong MO, Wagemaker G, Wognum AW: Separation of myeloid and erythroid progenitors based on expression of CD34 and c-kit. Blood 86:4076, 1995[Abstract/Free Full Text]
269. Olweus J, Terstappen LWMM, Thompson PA, Lund-Johansen F: Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Blood 88:1594, 1996[Abstract/Free Full Text]
270. Yee NS, Langen H, Besmer P: Mechanism of kit ligand, phorbol ester, and calcium-induced down-regulation of c-kit receptors in mast cells. J Biol Chem 268:14189, 1993[Abstract/Free Full Text]
271. Katayama N, Shih J-P, Nishikawa S, Kina T, Clark SC, Ogawa M: Stage-specific expression of c-kit protein by murine hematopoietic progenitors. Blood 82:2353, 1993[Abstract/Free Full Text]
272. Wang C, Curtis JE, Geissler EN, McCulloch EA, Minden MD: The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3:699, 1989[Medline] [Order article via Infotrieve]
273. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD: Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78:2962, 1991[Abstract/Free Full Text]
274. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID: Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 80:60, 1992[Abstract/Free Full Text]
275. Bühring H-J, Ullrich A, Schaudt K, Müller CA, Busch FW: The product of the proto-oncogene c-kit (P145^c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia 5:854, 1991[Medline] [Order article via Infotrieve]
276. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A: Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's Disease and CD30⁺ anaplastic large cell lymphomas. Blood 83:785, 1994[Abstract/Free Full Text]
277. Tomeczkowski J, Beilken A, Frick D, Wieland B, König A, Falk MH, Reiter A, Welte K, Sykora K-W: Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt's lymphoma cells. Blood 86:1469, 1995[Abstract/Free Full Text]
278. Hu Z-B, Ma W, Uphoff CC, Quentmeier H, Drexler HG: c-kit expression in human megakaryoblastic leukemia cell lines. Blood 83:2133, 1994[Abstract/Free Full Text]
279. Abkowitz JL, Broudy VC, Bennett LG, Zsebo KM, Martin FH: Absence of abnormalities of c-kit or its ligand in two patients with Diamond-Blackfan anemia. Blood 79:25, 1992[Abstract/Free Full Text]
280. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80:374, 1992[Abstract/Free Full Text]
281. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC, The Children's Cancer Group: Expression of stem cell factor and c-kit in human neuroblastoma. Blood 84:3465, 1994[Abstract/Free Full Text]
282. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51:2416, 1991[Abstract/Free Full Text]
283. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A: Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 52:6139, 1992[Abstract/Free Full Text]
284. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ: Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51:1811, 1991[Abstract/Free Full Text]
285. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmeyer HE: Ligand-dependent polyubiquitination of c-kit gene product: A possible mechanism of receptor down modulation in M07e cells. Blood 83:137, 1994[Abstract/Free Full Text]
286. Yee NS, Hsiau C-WM, Serve H, Vosseller K, Besmer P: Mechanism of down-regulation of c-kit receptor. J Biol Chem 269:31991, 1994[Abstract/Free Full Text]
287. Sorkin A, Waters CM: Endocytosis of growth factor receptors. Bioessays 15:375, 1993[Medline] [Order article via Infotrieve]
288. Dubois CM, Ruscetti FW, Stankova J, Keller JR: Transforming growth factor- $beta$ regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. Blood 83:3138, 1994[Abstract/Free Full Text]
289. Khoury E, Andre C, Pontvert-Delucq S, Drenou B, Baillou C, Guigon M, Najman A, Lemoine FM: Tumor necrosis factor $alpha$ (TNF $alpha$ ) downregulates c-kit proto-oncogene product expression in normal and acute myeloid leukemia CD34⁺ cells via p55 TNF $alpha$ receptors. Blood 84:2506, 1994[Abstract/Free Full Text]
290. Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P: IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147:4224, 1991[Abstract]
291. Rusten LS, Smeland EB, Jacobsen FW, Lien E, Lesslauer W, Loetscher H, Dubois CM, Jacobsen SEW: Tumor necrosis factor- $alpha$ inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. J Clin Invest 94:165, 1994
292. Brizzi MF, Blechman JM, Cavalloni G, Givol D, Yarden Y, Pegoraro L: Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF ) receptor by MGF-depdendent human myeloid cells. Oncogene 9:1583, 1994[Medline] [Order article via Infotrieve]
293. Rose-John S, Heinrich PC: Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 300:281, 1994
294. Heaney ML, Golde DW: Soluble cytokine receptors. Blood 87:847, 1996[Free Full Text]
295. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, zum Büschenfelde K-HM, Rose-John S: The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183:1399, 1996[Abstract/Free Full Text]
296. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp130. Blood 86:1243, 1995[Free Full Text]
297. Ku H, Hirayama F, Kato T, Miyazaki H, Aritomi M, Ota Y, D'Andrea AD, Lyman SD, Ogawa M: Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for flt3/flk2. Blood 88:4124, 1996[Abstract/Free Full Text]
298. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG: Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247:962, 1990[Abstract/Free Full Text]
299. Wypych J, Bennett LG, Schwartz MG, Clogston CL, Lu HS, Broudy VC, Bartley TD, Parker VP, Langley KE: Soluble Kit receptor in human serum. Blood 85:66, 1995[Abstract/Free Full Text]
300. Liu Y-C, Kawagishi M, Kameda R, Ohashi H: Characterization of a fusion protein composed of the extracellular domain of c-kit and the F_c region of human IgG expressed in a baculovirus system. Biochem Biophys Res Commun 197:1094, 1993[Medline] [Order article via Infotrieve]
301. Grichnik JM, Crawford J, Jimenez F, Kurtzberg J, Buchanan M, Blackwell S, Clark RE, Hitchcock MG: Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. J Am Acad Dermatol 33:577, 1995[Medline] [Order article via Infotrieve]
302. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J: Recombinant methionyl human stem cell factor and filgrastin for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients $---$ Results of a phase I/II trial. Blood 89:3136, 1997[Abstract/Free Full Text]
303. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Olson E, Wyres M, Parker W, Barlogie B: Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHuSCF (SCF ) and r-metHuG-CSF (Filgrastim) in heavily pretreated multiple myeloma (MM) patients. Blood 88:388a, 1996 (abstr, suppl 1)
304. Nocka KH, Levine BA, Ko J-L, Burch PM, Landgraf BE, Segal R, Lobell R: Increased growth promoting but not mast cell degranulation potential of a covalent dimer of c-Kit ligand. Blood (in press)
305. Nocka KH, Burch P, Levine BA, Undem B, Segal R, Nair N, Alessi MK, Landgraf BE, Lobell R: Human c-kit ligand analogue, SAF-9, with increased growth factor but not mast cell stimulating activity. Blood 88:548a, 1996 (abstr, suppl 1)
306. Luskey BD, Rosenblatt M, Zsebo K, Williams DA: Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells. Blood 80:396, 1992[Abstract/Free Full Text]
307. Williams DA: Ex vivo expansion of hematopoietic stem and progenitor cells $---$ Robbing Peter to pay Paul? Blood 81:3169, 1993[Free Full Text]
308. Emerson SG: Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapeutics. Blood 87:3082, 1996[Free Full Text]
309. Ratajczak MZ, Pletcher C, Marliez W, Wasik M, Machalinski B, Ratajczak J, Moore J, Gewirtz AM: A rapid method for isolating human hematopoietic stem cells (HHSC). Blood 88:109a, 1996 (abstr, suppl 1)
310. Kasahara N, Dozy AM, Kan YW: Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373, 1994[Abstract/Free Full Text]
311. Schwarzenberger P, Spence SE, Gooya JM, Michiel D, Curiel DT, Ruscetti FW, Keller JR: Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor. Blood 87:472, 1996[Abstract/Free Full Text]
312. Hsu Y-R, Wu G-M, Mendiaz EA, Syed R, Wypych J, Toso R, Mann MB, Boone TC, Narhi LO, Lu HS, Langley KE: The majority of stem cell factor exists as monomer under physiological conditions. J Biol Chem 272:6406, 1997[Abstract/Free Full Text]
313. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J: Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272:6311, 1997[Abstract/Free Full Text]

© 1997 by The American Society of Hematology.

Add to CiteULike CiteULike    Add to Connotea Connotea    Add to Del.icio.us Del.icio.us    Add to Digg Digg    Add to Reddit Reddit    Add to Technorati Technorati    What's this?

This article has been cited by other articles:

F. Cerisoli, L. Cassinelli, G. Lamorte, S. Citterio, F. Bertolotti, M. C. Magli, and S. Ottolenghi
Green fluorescent protein transgene driven by Kit regulatory sequences is expressed in hematopoietic stem cells
Haematologica, March 1, 2009; 94(3): 318 - 325.
[Abstract] [Full Text] [PDF]

C. Nishioka, T. Ikezoe, J. Yang, A. Miwa, T. Tasaka, Y. Kuwayama, K. Togitani, H. P. Koeffler, and A. Yokoyama
Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
Blood, May 15, 2008; 111(10): 5086 - 5092.
[Abstract] [Full Text] [PDF]

T. Hasegawa, D. S. McLeod, T. Prow, C. Merges, R. Grebe, and G. A. Lutty
Vascular Precursors in Developing Human Retina
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2178 - 2192.
[Abstract] [Full Text] [PDF]

D. Kent, M. Copley, C. Benz, B. Dykstra, M. Bowie, and C. Eaves
Regulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway
Clin. Cancer Res., April 1, 2008; 14(7): 1926 - 1930.
[Abstract] [Full Text] [PDF]

S. S. Fazel, L. Chen, D. Angoulvant, S.-H. Li, R. D. Weisel, A. Keating, and R.-K. Li
Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury
FASEB J, March 1, 2008; 22(3): 930 - 940.
[Abstract] [Full Text] [PDF]

L. A. Thoren, K. Liuba, D. Bryder, J. M. Nygren, C. T. Jensen, H. Qian, J. Antonchuk, and S.-E. W. Jacobsen
Kit Regulates Maintenance of Quiescent Hematopoietic Stem Cells
J. Immunol., February 15, 2008; 180(4): 2045 - 2053.
[Abstract] [Full Text] [PDF]

G. Stokman, J. C. Leemans, I. Stroo, I. Hoedemaeker, N. Claessen, G. J. D. Teske, J. J. Weening, and S. Florquin
Enhanced mobilization of bone marrow cells does not ameliorate renal fibrosis
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 483 - 491.
[Abstract] [Full Text] [PDF]

X.-L. Liu, J.-Y. Yuan, J.-W. Zhang, X.-H. Zhang, and R.-X. Wang
Differential gene expression in human hematopoietic stem cells specified toward erythroid, megakaryocytic, and granulocytic lineage
J. Leukoc. Biol., October 1, 2007; 82(4): 986 - 1002.
[Abstract] [Full Text] [PDF]

D. Filipponi, R. M. Hobbs, S. Ottolenghi, P. Rossi, E. A. Jannini, P. P. Pandolfi, and S. Dolci
Repression of kit Expression by Plzf in Germ Cells
Mol. Cell. Biol., October 1, 2007; 27(19): 6770 - 6781.
[Abstract] [Full Text] [PDF]

V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur
Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Blood, September 1, 2007; 110(5): 1612 - 1620.
[Abstract] [Full Text] [PDF]

C. Waskow, S. Bartels, S. M. Schlenner, C. Costa, and H.-R. Rodewald
Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin
Blood, June 15, 2007; 109(12): 5363 - 5370.
[Abstract] [Full Text] [PDF]

M. E. M. Van Meter, E. Diaz-Flores, J. A. Archard, E. Passegue, J. M. Irish, N. Kotecha, G. P. Nolan, K. Shannon, and B. S. Braun
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells
Blood, May 1, 2007; 109(9): 3945 - 3952.
[Abstract] [Full Text] [PDF]

C.-H. Wang, S. Verma, I-C. Hsieh, A. Hung, T.-T. Cheng, S.-Y. Wang, Y.-C. Liu, W. L. Stanford, R. D. Weisel, R.-K. Li, et al.
Stem Cell Factor Attenuates Vascular Smooth Muscle Apoptosis and Increases Intimal Hyperplasia After Vascular Injury
Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 540 - 547.
[Abstract] [Full Text] [PDF]

S. Ito, C. R. Mantel, M.-K. Han, S. Basu, S. Fukuda, S. Cooper, and H. E. Broxmeyer
Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells
Blood, March 1, 2007; 109(5): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Z. Xiang, F. Kreisel, J. Cain, A. Colson, and M. H. Tomasson
Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling
Mol. Cell. Biol., January 1, 2007; 27(1): 267 - 282.
[Abstract] [Full Text] [PDF]

A. J. Laing, J. P. Dillon, E.T. Condon, J. C. Coffey, J. T. Street, J. H. Wang, A. J. McGuinness, and H. P. Redmond
A systemic provascular response in bone marrow to musculoskeletal trauma in mice
J Bone Joint Surg Br, January 1, 2007; 89-B(1): 116 - 120.
[Abstract] [Full Text] [PDF]

J. M. Shammo and F. M. Stewart
Hematopoietic growth factors
ASH Self-Assessment Program, January 1, 2007; 2007(1): 45 - 60.
[Full Text] [PDF]

M. Zareie, P. Fabbrini, L. H.P. Hekking, E. D. Keuning, P. M. ter Wee, R. H.J. Beelen, and J. van den Born
Novel Role for Mast Cells in Omental Tissue Remodeling and Cell Recruitment in Experimental Peritoneal Dialysis
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3447 - 3457.
[Abstract] [Full Text] [PDF]

T. Ikezoe, C. Nishioka, T. Tasaka, Y. Yang, N. Komatsu, K. Togitani, H. P. Koeffler, and H. Taguchi
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Mol. Cancer Ther., October 1, 2006; 5(10): 2522 - 2530.
[Abstract] [Full Text] [PDF]

G. Berrozpe, V. Agosti, C. Tucker, C. Blanpain, K. Manova, and P. Besmer
A Distant Upstream Locus Control Region Is Critical for Expression of the Kit Receptor Gene in Mast Cells
Mol. Cell. Biol., August 1, 2006; 26(15): 5850 - 5860.
[Abstract] [Full Text] [PDF]

J. Li, D. P. Sejas, R. Rani, T. Koretsky, G. C. Bagby, and Q. Pang
Nucleophosmin Regulates Cell Cycle Progression and Stress Response in Hematopoietic Stem/Progenitor Cells
J. Biol. Chem., June 16, 2006; 281(24): 16536 - 16545.
[Abstract] [Full Text] [PDF]

D. C. Goldman, L. K. Berg, M. C. Heinrich, and J. L. Christian
Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus
Blood, April 15, 2006; 107(8): 3114 - 3121.
[Abstract] [Full Text] [PDF]

Y. Nagasawa, B. L. Wood, L. Wang, I. Lintmaer, W. Guo, T. Papayannopoulou, M. A. Harkey, C. Nourigat, and C. A. Blau
Anatomical Compartments Modify the Response of Human Hematopoietic Cells to a Mitogenic Signal
Stem Cells, April 1, 2006; 24(4): 908 - 917.
[Abstract] [Full Text] [PDF]

S. Nandi, M. P. Akhter, M. F. Seifert, X.-M. Dai, and E. R. Stanley
Developmental and functional significance of the CSF-1 proteoglycan chondroitin sulfate chain
Blood, January 15, 2006; 107(2): 786 - 795.
[Abstract] [Full Text] [PDF]

S. Keslacy, R. S. Mazzeo, D. A. Giussani, A. S. Thakor, G. Insalaco, M. R. Bonsignore, F. A. Rodriguez, K. S. Mark, C. Reboul, S. Tanguy, et al.
Commentary on Point-Counterpoint
J Appl Physiol, January 1, 2006; 100(1): 363 - 363.
[Full Text] [PDF]

D. Zohlnhofer, J. Hausleiter, A. Kastrati, J. Mehilli, C. Goos, H. Schuhlen, J. Pache, G. Pogatsa-Murray, U. Heemann, J. Dirschinger, et al.
A Randomized, Double-Blind, Placebo-Controlled Trial on Restenosis Prevention by the Receptor Tyrosine Kinase Inhibitor Imatinib
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1999 - 2003.
[Abstract] [Full Text] [PDF]

B. Heissig, S. Rafii, H. Akiyama, Y. Ohki, Y. Sato, T. Rafael, Z. Zhu, D. J. Hicklin, K. Okumura, H. Ogawa, et al.
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization
J. Exp. Med., September 19, 2005; 202(6): 739 - 750.
[Abstract] [Full Text] [PDF]

M. Komor, S. Guller, C. D. Baldus, S. de Vos, D. Hoelzer, O. G. Ottmann, and W.-K. Hofmann
Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage-Specific Differentiation
Stem Cells, September 1, 2005; 23(8): 1154 - 1169.
[Abstract] [Full Text] [PDF]

V. Munugalavadla, L. C. Dore, B. L. Tan, L. Hong, M. Vishnu, M. J. Weiss, and R. Kapur
Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation
Mol. Cell. Biol., August 1, 2005; 25(15): 6747 - 6759.
[Abstract] [Full Text] [PDF]

J. D. Growney, J. J. Clark, J. Adelsperger, R. Stone, D. Fabbro, J. D. Griffin, and D. G. Gilliland
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412
Blood, July 15, 2005; 106(2): 721 - 724.
[Abstract] [Full Text] [PDF]

H. K. Haider and M. Ashraf
Bone marrow stem cell transplantation for cardiac repair
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2557 - H2567.
[Abstract] [Full Text] [PDF]

C. Tarn, E. Merkel, A. A. Canutescu, W. Shen, Y. Skorobogatko, M. J. Heslin, B. Eisenberg, R. Birbe, A. Patchefsky, R. Dunbrack, et al.
Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling
Clin. Cancer Res., May 15, 2005; 11(10): 3668 - 3677.
[Abstract] [Full Text] [PDF]

C. Xu, E. Rosler, J. Jiang, J. S. Lebkowski, J. D. Gold, C. O'Sullivan, K. Delavan-Boorsma, M. Mok, A. Bronstein, and M. K. Carpenter
Basic Fibroblast Growth Factor Supports Undifferentiated Human Embryonic Stem Cell Growth Without Conditioned Medium
Stem Cells, March 1, 2005; 23(3): 315 - 323.
[Abstract] [Full Text] [PDF]

A. L. Drayer, A.-K. Boer, E. L. Los, M. T. Esselink, and E. Vellenga
Stem Cell Factor Synergistically Enhances Thrombopoietin-Induced STAT5 Signaling in Megakaryocyte Progenitors through JAK2 and Src Kinase
Stem Cells, February 1, 2005; 23(2): 240 - 251.
[Abstract] [Full Text] [PDF]

J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Stem Cells, January 1, 2005; 23(1): 16 - 43.
[Abstract] [Full Text] [PDF]

R. R. Sivalenka and R. Jessberger
SWAP-70 Regulates c-kit-Induced Mast Cell Activation, Cell-Cell Adhesion, and Migration
Mol. Cell. Biol., December 1, 2004; 24(23): 10277 - 10288.
[Abstract] [Full Text] [PDF]

A. Slominski, D. J. Tobin, S. Shibahara, and J. Wortsman
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
Physiol Rev, October 1, 2004; 84(4): 1155 - 1228.
[Abstract] [Full Text] [PDF]

Q. Tian, S. B. Stepaniants, M. Mao, L. Weng, M. C. Feetham, M. J. Doyle, E. C. Yi, H. Dai, V. Thorsson, J. Eng, et al.
Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells
Mol. Cell. Proteomics, October 1, 2004; 3(10): 960 - 969.
[Abstract] [Full Text] [PDF]

C. Waskow, G. Terszowski, C. Costa, M. Gassmann, and H.-R. Rodewald
Rescue of lethal c-KitW/W mice by erythropoietin
Blood, September 15, 2004; 104(6): 1688 - 1695.
[Abstract] [Full Text] [PDF]

J. Antonchuk, C. D. Hyland, D. J. Hilton, and W. S. Alexander
Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors
Blood, September 1, 2004; 104(5): 1306 - 1313.
[Abstract] [Full Text] [PDF]

E. Paietta, A. A. Ferrando, D. Neuberg, J. M. Bennett, J. Racevskis, H. Lazarus, G. Dewald, J. M. Rowe, P. H. Wiernik, M. S. Tallman, et al.
Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias
Blood, July 15, 2004; 104(2): 558 - 560.
[Abstract] [Full Text] [PDF]

C. Hart, D. Drewel, G. Mueller, J. Grassinger, M. Zaiss, L. A. Kunz-Schughart, R. Andreesen, A. Reichle, E. Holler, and B. Hennemann
Expression and Function of Homing-Essential Molecules and Enhanced In Vivo Homing Ability of Human Peripheral Blood-Derived Hematopoietic Progenitor Cells after Stimulation with Stem Cell Factor
Stem Cells, July 1, 2004; 22(4): 580 - 589.
[Abstract] [Full Text] [PDF]

K. Kuramoto, D. A. Follmann, P. Hematti, S. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, C. von Kalle, and C. E. Dunbar
Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates
Blood, June 1, 2004; 103(11): 4070 - 4077.
[Abstract] [Full Text] [PDF]

P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
Blood, April 15, 2004; 103(8): 2929 - 2935.
[Abstract] [Full Text] [PDF]

C. C. Zhang and H. F. Lodish
Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells
Blood, April 1, 2004; 103(7): 2513 - 2521.
[Abstract] [Full Text] [PDF]

J. N. Cormier and R. E. Pollock
Soft Tissue Sarcomas
CA Cancer J Clin, March 1, 2004; 54(2): 94 - 109.
[Abstract] [Full Text] [PDF]

H. Shibayama, E. Takai, I. Matsumura, M. Kouno, E. Morii, Y. Kitamura, J. Takeda, and Y. Kanakura
Identification of a Cytokine-induced Antiapoptotic Molecule Anamorsin Essential for Definitive Hematopoiesis
J. Exp. Med., February 17, 2004; 199(4): 581 - 592.
[Abstract] [Full Text] [PDF]

L. Hong, V. Munugalavadla, and R. Kapur
c-Kit-Mediated Overlapping and Unique Functional and Biochemical Outcomes via Diverse Signaling Pathways
Mol. Cell. Biol., February 1, 2004; 24(3): 1401 - 1410.
[Abstract] [Full Text] [PDF]

W. J. Bakker, M. Blazquez-Domingo, A. Kolbus, J. Besooyen, P. Steinlein, H. Beug, P. J. Coffer, B. Lowenberg, M. von Lindern, and T. B. van Dijk
FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1
J. Cell Biol., January 19, 2004; 164(2): 175 - 184.
[Abstract] [Full Text] [PDF]

I. Nobuhisa, M. Takizawa, S. Takaki, H. Inoue, K. Okita, M. Ueno, K. Takatsu, and T. Taga
Regulation of Hematopoietic Development in the Aorta-Gonad-Mesonephros Region Mediated by Lnk Adaptor Protein
Mol. Cell. Biol., December 1, 2003; 23(23): 8486 - 8494.
[Abstract] [Full Text] [PDF]

K. Takeuchi, K. Koike, T. Kamijo, S. Ishida, Y. Nakazawa, Y. Kurokawa, K. Sakashita, T. Kinoshita, S. Matsuzawa, M. Shiohara, et al.
STI571 inhibits growth and adhesion of human mast cells in culture
J. Leukoc. Biol., December 1, 2003; 74(6): 1026 - 1034.
[Abstract] [Full Text]

L. A. Cairns, E. Moroni, E. Levantini, A. Giorgetti, F. G. Klinger, S. Ronzoni, L. Tatangelo, C. Tiveron, M. De Felici, S. Dolci, et al.
Kit regulatory elements required for expression in developing hematopoietic and germ cell lineages
Blood, December 1, 2003; 102(12): 3954 - 3962.
[Abstract] [Full Text] [PDF]

S. Bottardi, A. Aumont, F. Grosveld, and E. Milot
Developmental stage-specific epigenetic control of human {beta}-globin gene expression is potentiated in hematopoietic progenitor cells prior to their transcriptional activation
Blood, December 1, 2003; 102(12): 3989 - 3997.
[Abstract] [Full Text] [PDF]

S. Chandra, R. Kapur, N. Chuzhanova, V. Summey, D. Prentice, J. Barker, D. N. Cooper, and D. A. Williams
A rare complex DNA rearrangement in the murine Steel gene results in exon duplication and a lethal phenotype
Blood, November 15, 2003; 102(10): 3548 - 3555.
[Abstract] [Full Text] [PDF]

A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria
Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins
Blood, July 1, 2003; 102(1): 87 - 93.
[Abstract] [Full Text] [PDF]

B. L. Tan, L. Hong, V. Munugalavadla, and R. Kapur
Functional and Biochemical Consequences of Abrogating the Activation of Multiple Diverse Early Signaling Pathways in Kit. ROLE FOR Src KINASE PATHWAY IN KIT-INDUCED COOPERATION WITH ERYTHROPOIETIN RECEPTOR
J. Biol. Chem., March 21, 2003; 278(13): 11686 - 11695.
[Abstract] [Full Text] [PDF]

D. A. Ingram, M. J. Wenning, K. Shannon, and D. W. Clapp
Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells
Blood, March 1, 2003; 101(5): 1984 - 1986.
[Abstract] [Full Text] [PDF]

L. Tatton, G. M. Morley, R. Chopra, and A. Khwaja
The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases
J. Biol. Chem., February 7, 2003; 278(7): 4847 - 4853.
[Abstract] [Full Text] [PDF]

A. Rich, S. M. Miller, S. J. Gibbons, J. Malysz, J. H. Szurszewski, and G. Farrugia
Local presentation of Steel factor increases expression of c-kit immunoreactive interstitial cells of Cajal in culture
Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G313 - G320.
[Abstract] [Full Text] [PDF]

D. Zemke, B. Yamini, and V. Yuzbasiyan-Gurkan
Mutations in the Juxtamembrane Domain of c-KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs
Vet. Pathol., September 1, 2002; 39(5): 529 - 535.
[Abstract] [Full Text] [PDF]

H. Tsujimura, T. Nagamura-Inoue, T. Tamura, and K. Ozato
IFN Consensus Sequence Binding Protein/IFN Regulatory Factor-8 Guides Bone Marrow Progenitor Cells Toward the Macrophage Lineage
J. Immunol., August 1, 2002; 169(3): 1261 - 1269.
[Abstract] [Full Text] [PDF]

J. Perez-Losada, M. Sanchez-Martin, A. Rodriguez-Garcia, M. L. Sanchez, A. Orfao, T. Flores, and I. Sanchez-Garcia
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway
Blood, July 30, 2002; 100(4): 1274 - 1286.
[Abstract] [Full Text] [PDF]

R. Kapur, S. Chandra, R. Cooper, J. McCarthy, and D. A. Williams
Role of p38 and ERK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor
Blood, July 30, 2002; 100(4): 1287 - 1293.
[Abstract] [Full Text] [PDF]

J. Soboloff and S. A. Berger
Sustained ER Ca2+ Depletion Suppresses Protein Synthesis and Induces Activation-enhanced Cell Death in Mast Cells
J. Biol. Chem., April 12, 2002; 277(16): 13812 - 13820.
[Abstract] [Full Text] [PDF]

C. P. Miller, D. W. Heilman, and D. M. Wojchowski
Erythropoietin receptor-dependent erythroid colony-forming unit development: capacities of Y343 and phosphotyrosine-null receptor forms
Blood, February 1, 2002; 99(3): 898 - 904.
[Abstract] [Full Text] [PDF]

S. Takaki, H. Morita, Y. Tezuka, and K. Takatsu
Enhanced Hematopoiesis by Hematopoietic Progenitor Cells Lacking Intracellular Adaptor Protein, Lnk
J. Exp. Med., January 14, 2002; 195(2): 151 - 160.
[Abstract] [Full Text] [PDF]

S. Page, A. J. Ammit, J. L. Black, and C. L. Armour
Human mast cell and airway smooth muscle cell interactions: implications for asthma
Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1313 - L1323.
[Abstract] [Full Text] [PDF]

B. Scappini, F. Onida, H. M. Kantarjian, L. Dong, S. Verstovsek, M. J. Keating, and M. Beran
Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells
Clin. Cancer Res., December 1, 2001; 7(12): 3884 - 3893.
[Abstract] [Full Text] [PDF]

Q. Zhong, P. Oliver, W. Huang, D. Good, V. La Russa, Z. Zhang, J. R. Cork, R. W. Veith, C. Theodossiou, J. K. Kolls, et al.
Efficient c-kit Receptor-Targeted Gene Transfer to Primary Human CD34-Selected Hematopoietic Stem Cells
J. Virol., November 1, 2001; 75(21): 10393 - 10400.
[Abstract] [Full Text] [PDF]

R. Chian, S. Young, A. Danilkovitch-Miagkova, L. Ronnstrand, E. Leonard, P. Ferrao, L. Ashman, and D. Linnekin
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
Blood, September 1, 2001; 98(5): 1365 - 1373.
[Abstract] [Full Text] [PDF]

B. O'Laughlin-Bunner, N. Radosevic, M. L. Taylor, Shivakrupa, C. DeBerry, D. D. Metcalfe, M. Zhou, C. Lowell, and D. Linnekin
Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells
Blood, July 15, 2001; 98(2): 343 - 350.
[Abstract] [Full Text] [PDF]

G. W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, L. Sun, G. McMahon, and K. E. Lipson
Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells
Cancer Res., May 1, 2001; 61(9): 3660 - 3668.
[Abstract] [Full Text]

R. Kapur, R. Cooper, L. Zhang, and D. A. Williams
Cross-talk between {alpha}4{beta}1/{alpha}5{beta}1 and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways
Blood, April 1, 2001; 97(7): 1975 - 1981.
[Abstract] [Full Text] [PDF]

M.-L. Hartman, A. M. Piliponsky, V. Temkin, and F. Levi-Schaffer
Human peripheral blood eosinophils express stem cell factor
Blood, February 15, 2001; 97(4): 1086 - 1091.
[Abstract] [Full Text] [PDF]

F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology, January 1, 2001; 2001(1): 62 - 86.
[Abstract] [Full Text] [PDF]

M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
Blood, August 1, 2000; 96(3): 925 - 932.
[Abstract] [Full Text] [PDF]

Z. Zhang, R. Zhang, A. Joachimiak, J. Schlessinger, and X.-P. Kong
Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation
PNAS, July 5, 2000; 97(14): 7732 - 7737.
[Abstract] [Full Text] [PDF]

D. W. Lee, K. Zhang, Z.-Q. Ning, E. H. Raabe, S. Tintner, R. Wieland, B. J. Wilkins, J. M. Kim, R. I. Blough, and R. J. Arceci
Proliferation-associated SNF2-like Gene (PASG): A SNF2 Family Member Altered in Leukemia1
Cancer Res., July 1, 2000; 60(13): 3612 - 3622.
[Abstract] [Full Text]

S. Fang, R. Steinmetz, D. W. King, P. Zeng, C. Vogelweid, S. Cooper, G. Hangcoc, H. E. Broxmeyer, and O. H. Pescovitz
Development of a Transgenic Mouse That Overexpresses a Novel Product of the Growth Hormone-Releasing Hormone Gene
Endocrinology, April 1, 2000; 141(4): 1377 - 1383.
[Abstract] [Full Text] [PDF]

D. A. Ingram, F.-C. Yang, J. B. Travers, M. J. Wenning, K. Hiatt, S. New, A. Hood, K. Shannon, D. A. Williams, and D. W. Clapp
Genetic and Biochemical Evidence that Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates In Vivo
J. Exp. Med., January 3, 2000; 191(1): 181 - 188.
[Abstract] [Full Text] [PDF]

O. J. Borge, J. Adolfsson, and A. M. I.-L. M. a. S. E.W. Jacobsen
Lymphoid-Restricted Development From Multipotent Candidate Murine Stem Cells: Distinct and Complimentary Functions of the c-kit and flt3-Ligands
Blood, December 1, 1999; 94(11): 3781 - 3790.
[Abstract] [Full Text] [PDF]

A. Bauer, F. Tronche, O. Wessely, C. Kellendonk, H. M. Reichardt, P. Steinlein, G. Schütz, and H. Beug
The glucocorticoid receptor is required for stress erythropoiesis
Genes & Dev., November 15, 1999; 13(22): 2996 - 3002.
[Abstract] [Full Text]

V. C. Broudy, N. L. Lin, W. C. Liles, S. J. Corey, B. O'Laughlin, S. Mou, and D. Linnekin
Signaling via Src Family Kinases Is Required for Normal Internalization of the Receptor c-Kit
Blood, September 15, 1999; 94(6): 1979 - 1986.
[Abstract] [Full Text] [PDF]

P. J. Roberts, E. Mollapour, M. J. Watts, and D. C. Linch
Primitive Myeloid Cells Express High Levels of Phospholipase A2 Activity in the Absence of Leukotriene Release: Selective Regulation by Stem Cell Factor Involving the MAP Kinase Pathway
Blood, August 15, 1999; 94(4): 1261 - 1272.
[Abstract] [Full Text] [PDF]

R. C. Fisher, J. D. Lovelock, and E. W. Scott
A Critical Role for PU.1 in Homing and Long-Term Engraftment by Hematopoietic Stem Cells in the Bone Marrow
Blood, August 15, 1999; 94(4): 1283 - 1290.
[Abstract] [Full Text] [PDF]

J. S. Smith, J. R. Keller, N. C. Lohrey, C. S. McCauslin, M. Ortiz, K. Cowan, and S. E. Spence
Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens
PNAS, August 3, 1999; 96(16): 8855 - 8860.
[Abstract] [Full Text] [PDF]

E. J. Shpall, C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, K. F. Mangan, S. F. Williams, C. F. LeMaistre, et al.
A Randomized Phase 3�Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients
Blood, April 15, 1999; 93(8): 2491 - 2501.
[Abstract] [Full Text] [PDF]

D. Parichy, J. Rawls, S. Pratt, T. Whitfield, and S. Johnson
Zebrafish sparse corresponds to an orthologue of c-kit and is required for the morphogenesis of a subpopulation of melanocytes, but is not essential for hematopoiesis or primordial germ cell development
Development, January 8, 1999; 126(15): 3425 - 3436.
[Abstract] [PDF]

M. Maurer, B. Echtenacher, L. Hultner, G. Kollias, D. N. Mannel, K. E. Langley, and S. J. Galli
The c-kit Ligand, Stem Cell Factor, Can Enhance Innate Immunity Through Effects on Mast Cells
J. Exp. Med., December 21, 1998; 188(12): 2343 - 2348.
[Abstract] [Full Text] [PDF]

N. R. Leslie, J. O'Prey, C. Bartholomew, and P. R. Harrison
An Activating Mutation in the Kit Receptor Abolishes the Stroma Requirement for Growth of ELM Erythroleukemia Cells, But Does Not Prevent Their Differentiation in Response to Erythropoietin
Blood, December 15, 1998; 92(12): 4798 - 4807.
[Abstract] [Full Text] [PDF]

B. Panzenbock, P. Bartunek, M. Y. Mapara, and M. Zenke
Growth and Differentiation of Human Stem Cell Factor/Erythropoietin-Dependent Erythroid Progenitor Cells In Vitro
Blood, November 15, 1998; 92(10): 3658 - 3668.
[Abstract] [Full Text] [PDF]

K. Kaushansky
Thrombopoietin and the Hematopoietic Stem Cell
Blood, July 1, 1998; 92(1): 1 - 3.
[Full Text] [PDF]

S. D. Lyman and S. E. W. Jacobsen
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
Blood, February 15, 1998; 91(4): 1101 - 1134.
[Full Text] [PDF]

V. C. Broudy, N. L. Lin, H.-J. Buhring, N. Komatsu, and T. J. Kavanagh
Analysis of c-kit Receptor Dimerization by Fluorescence Resonance Energy Transfer
Blood, February 1, 1998; 91(3): 898 - 906.
[Abstract] [Full Text] [PDF]

T Kunisada, H Yoshida, H Yamazaki, A Miyamoto, H Hemmi, E Nishimura, L. Shultz, S Nishikawa, and S Hayashi
Transgene expression of steel factor in the basal layer of epidermis promotes survival, proliferation, differentiation and migration of melanocyte precursors
Development, January 8, 1998; 125(15): 2915 - 2923.
[Abstract] [PDF]

A. M. Dvorak, J. J. Costa, E. S. Morgan, R. A. Monahan-Earley, and S. J. Galli
Diamine Oxidase-Gold Ultrastructural Localization of Histamine in Human Skin Biopsies Containing Mast Cells Stimulated to Degranulate In Vivo by Exposure to Recombinant Human Stem Cell Factor
Blood, October 15, 1997; 90(8): 2893 - 2900.
[Abstract] [Full Text] [PDF]

T. J. Pircher, J. N. Geiger, D. Zhang, C. P. Miller, P. Gaines, and D. M. Wojchowski
Integrative Signaling by Minimal Erythropoietin Receptor Forms and c-Kit
J. Biol. Chem., March 16, 2001; 276(12): 8995 - 9002.
[Abstract] [Full Text] [PDF]

This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Citation Map

Services

Email this article to a friend

Similar articles in this journal

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Rights and Permissions

Citing Articles

Citing Articles via HighWire

Citing Articles via CrossRef

Citing Articles via Google Scholar

Google Scholar

Articles by Broudy, V. C.

Search for Related Content

PubMed

PubMed Citation

Articles by Broudy, V. C.

Related Collections

Review Articles

Social Bookmarking


What's this?

  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020





	Copyright © 1997 by American Society of Hematology Online ISSN: 1528-0020

Blood, Vol. 90 No. 4 (August 15), 1997: pp. 1345-1364

Stem Cell Factor and Hematopoiesis

© 1997 by The American Society of Hematology.